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Abstract 
Drug resistance is a major problem in cancer chemotherapy. By modifying the 
signalling pathway in cells, the sensitivity of cells to anti-cancer drugs might be altered. 
This new approach can enhance the anti-tumor sensitivity of the drugs instead of using 
high doses of the drugs. The detail of how the growth factor signalling pathway 
interacts with drug sensitivity mechanism is still not yet clear. By comparing the human 
squamous carcinoma A431 sublines, the inter-relationship between the drug resistance 
and growth factor signalling pathway were studied. 
Results from the current studies suggested that the cisplatin resistance mechanisms in 
A431 cisplatin resistant cells might be related to reduction in drug induced DNA 
fragmentation, mitochondrial membrane depolarization, reactive oxygen species 
(superoxide oxide) formation, DNA repair and platinum uptake but not related to P-
glycoprotein, glutathione and glutathione-S-transferase content. After selection thru 
cisplatin, A431/CP500N cells were more responsive to EGF inhibitory effect and the 
EGFR activity and its expression were altered. To investigate how growth factor 
signalling modifies drug sensitivity, A431 cells were under prolonged incubation with 
EGF with (A431/CP500E cells) or without (A431/50X30 cells) cisplatin selection. As 
compared to the parent cells, the EGF conditioned cells were no longer growth inhibited 
but stimulated by EGF. They had inactivated EGFR activity and also exhibited different 
responsive pattern to other growth factors and growth factor signalling modifiers (in 
particular the cells were more resistant to okadic acid) as compared to parent cells. In 
X 
term of drug sensitivity pattern, the EGF conditioned cells were at least more resistant to 
5-fluorouracil than that of the parent cells. Furthermore, concomitant conditioning of 
cells in EGF and cisplatin would suppress the development of cisplatin resistance. To 
explore the mechanisms for this suppression effect, the technique of differential display 
was employed. A novel gene was identified to be down-regulated in A431/CP500N 
cells but not in parent and A431/CP500E cells. Furthermore characterization is needed 
once the full length of the clone was isolated. Finally, results from the present study do 
support that growth factor signalling pathway may interact with drug sensitivity 
mechanisms in many ways. The cell lines established will be very useful for a detailed 
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The mechanisms of drug resistance and signalling pathways are still not yet fully 
understood. Since their effects might be inter-related, it is of interest to study the inter-
relationship between the drug resistance mechanisms and the growth factor signalling 
pathway in the cells. 
Cisplatin is known to be a successful anti-cancer drug in the treatment of several 
carcinomas such as ovarian and testicular carcinoma (Gelasco and Lippard, 1999; Heim, 
1993; Keppler, 1993 and Natile and Coluccia, 1999). However，treatment of these 
cancers is often limited by the occurrence of cisplatin resistant phenotype. The 
mechanisms related to drug resistance are generally due to the presence of detoxification 
agents and DNA repair protein, and the decreased level of drug accumulations. 
Nowadays，it showed that the resistance mechanism might also be due to the alteration of 
signalling pathway. This phenomenon also arouses the idea of how the growth factor 
signalling might affect the cisplatin resistance in cells. 
EGF is one of the most commonly studied growth factor. After the binding of EGF to 
specific cell surface EGFR，a number of cellular responses was induced. Modification 
of growth factor signalling pathway would affect the cellular response to several anti-
cancer drugs, and it might also alter the drug resistance mechanisms. One might wonder 
how the relationships between the signalling pathway and drug resistance mechanisms 
are. 
1 
A431 cells were used in this study. The cells were used in many different laboratories 
for the study of growth factor signalling pathway, especially the well-characterized EGFR 
pathway. Various A431 sublines were derived from A431 cells based on the 
conditioned treatment of cisplatin with / without EGF. This project is divided into three 
different parts. First of all, the cisplatin resistance mechanisms were studied using a 
cisplatin resistant A431 subline. In the second part, the relationship between the drug 
resistance mechanisms and the growth factor signalling pathway were examined using 
cells derived from different pre-conditioning treatment. Other than the cellular response 




CISPLATIN RESISTANCE MECHANISMS 
1.1 INTRODUCTION 
Cisplatin [cis-dianiniinedichloroplatinum(II) (CDDP) or cis-DDP] is one of the most 
widely used and successful drugs in cancer chemotherapy. It showed amazingly good 
effects on various advanced tumors. Today，cisplatin is frequently used in combination 
with other antitumor agents (such as bleomycin, doxorubicin, taxol or 5-fluorouracil). 
It is effectively against testicular carcinomas, ovarian carcinomas, bladder tumors, and 
head and neck squamous carcinomas (Gelasco and Lippard, 1999 and Keppler, 1993). 
However, treatment of these cancers is often limited by the occurrence of cisplatin-
resistance in the cells. Therefore, to improve the efficacy of using cisplatin in cancer 
therapy, understanding the cisplatin resistance mechanism is very important. 
1.1.1 History of Cisplatin as an Anticancer Drug 
Cisplatin is widely used in clinic today. The drug was first synthesized in 1844 by 
Michele Peyrone; and the tumor-inhibiting effects were discovered by Barnett Rosenberg 
in 1969. By submerging the platinum electrode in a solution of ammonium chloride, 
ammonium hexachloroplatinuate, (NH4)2PtCl6，was formed which could photochemically 
converted into cis-diamminetetrachlroplatinum (IV), cis-Pt(NH3)2Cl4，by sunlight during 
the experiment (Keppler, 1993). The photochemical conversion is shown in the 
following equation: 
3 
陶么 __挑 + 2 HCf 
These end-products was found to inhibit bacterial cell growth. Afterwards, some simple 
platinum complexes, cis-Pt(NH3)2Cl4，cis-Pt(NH3)2Cl2，PtenCl。，and PtenCl4 (Fig. 1) were 
tested on animals bearing either sarcoma 180 or L1210 leukemia. All these cis-
configurated compounds exhibited an outstanding tumor-inhibiting effect in the animal 
experiments. In contrast to this, the corresponding trans-compounds were found to be 
inactive (Keppler, 1993). 
4 
� H j N C I H - N C I 
Pt Pt 
L H ^ N C I H 3 N C I 
l,2-Diaminoethanedichloroplatinunn(ll) c/s-Diamminedichloroplatinum(ll) 
CI c i 
r — CI H3N- c ! 
; \ o + Z i ” \ ^ ： ； y Pt ; : P t 
: z \ : i z \ i 
L H j N - - - - - C I H 3 N C I 
CI C I 
1,2-Diamlnoethanetetrachioroplatinum(tV) c/s-Diamminetetrachlorop(atinum(IV) 
Figure 1. The structures of platinum complexes. 
Later on, cisplatin was found to be very effective against a variety of solid tumors in 
animal models. In 1971，the drug entered clinical trials and established as a highly 
effective drug in the treatment of testicular and ovarian cancers (Lebwohl and Canetta， 
1998). Recently, the drug has been proven to be beneficial in the treatment of a wide 
variety of tumors (Table 1) (Keppler，1993). 
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Table 1: Clinical activity of cisplatin 
• Germ cell tumors “ 
• Ovarian cancer 
• Bladder cancer 
• Head and neck cancer 
• Esophageal cancer 
• Lung cancer (small cell and non-small cell) 
• Cervical carcinomas 
• Sarcomas 
• Brain tumors 
• Malignant lymphomas, thymoma 
• Gastric adenocarcinoma 
• Breast cancer 
The presence of side effects associated with cisplatin treatment have given the impetus to 
the development of two cisplatin analogs, namely carboplatin and oxaliplatin (Fig. 2) 
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Figure 2. The structures of cisplatin and its analogs. 
Carboplaiin was synthesized by the substitution of the more stable 
cyclobutancdicarbosxyhc tor the two chlorides. This drug diminishes (he renal cftccis, 
produces substantially less nausea, vomiting, and neurotoxicity, and dose-limiting 
toxic"), on myclosupprcssion (Asada ev uL�1998: Belvedere et uL’ 19% and Bucana et 
ill., IWO). 
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1.1.2 Active Mechanisms of Cisplatin 
Cisplatin in solution is hydrolyzed first before binding to DNA. The hydrolysis of 
cisplatin in aqueous solution will first form the monosubstituted [Pt(NH3)2(H20)Cl]+ and 
eventually the diaqua [Pt(NH3)2(H20)2]2+ species (Fig. 3) (Chu，1994). The first 
hydrolysis reaction activates cisplatin for its binding with DNA. The monofunctional 
aqua intermediate binds to the N7 atom of the quanine residue through displacement of 
water and not chloride ions (Gelasco and Lippard, 1999). 
H2O H2O 
Pt(MH3)2a2 入 \ > P t C N H s l s C K H s O -入 > 
� A � • 
Cf cr 
Pt(NH3)2Cl(OH) P!(NH3)2(0H){H20)-
Figure 3. Hydrolysis of cisplatin. 
Only the hydrolyzed cisplatin can demonstrate the tumor-inhibitory effect. Cisplatin 
inhibits the growth of tumor by inhibiting DNA synthesis, forming DNA fragments and 
adducts, and arresting the cells at S phase (Ishikawa et al., 1994; Lanzi et aL, 1998 and 
Zhang et al., 1998). 
1.1.3 Formation of DNA Adducts 
The cytotoxicity of cisplatin is believed to be due to the formation of DNA adducts, 
8 
which include DNA-protein cross-links, DNA monoadducts, and interstrand and 
intrastrand DNA cross-links (Chu, 1994 and Zamble and Lippard, 1995). The most 
frequently studied one was the DNA-adducts. In the in vitro studies using platinated 
oligonulceotides, the major adduct (80%) formed is the 1,2-intrastrand cross-link between 
the N7 positions of adjacent purine bases. Other minor products included the interstrand 
G-Pt-G adduct formed at GC sites and monofunctional Pt-G adducts. In the 1,2-
intrastrand, 65% of platinum are [Pt(NH3)2{d(GpG-N7(lXN7(2))}] while 20% of them 
are [Pt(NH3)2{d(ApG-N7(l),N7(2))}]. 
Figure 4. Cisplatin DNA adducts. (a) 1,2-d(GpG)-intrastrand crosslink, (b) 1,2-
d(ApG)-intrastand crosslink. 
1.1.4 Cisplatin Resistance Mechanisms 
Cisplatin can inhibit the growth of tumor cells. It has been widely used in cancer 
chemotherapy. Similar to other anticancer drugs, several side effects were observed. 
These included nausea, vomiting, ototoxicity, hypomagnesemia, myelosuppression, 
peripheral neurotoxicity, nephrotoxicity, etc. Some of the side effect such as 
9 
nephrotoxicity can be avoided by fractionated therapy schemes and forced diuresis with 
hyperhydration (Cole and Deeley，1996; Deeley and Cole, 1997; Ford et al., 1996; 
Hickson and Hochhauser，1997; Kelley and Rozencweig，1989 and Lebwohl and Canetta, 
1998). 
Apart from the above side effects, one of the major concerns for using cisplatin in cancer 
treatment is the development of drug resistance. Resistance is manifested as a tolerance 
of cells to the treatment with a toxic concentration of a drug. Resistance against 
cisplatin is a major problem for chemotherapy (Chu, 1994; Cnil et al, 1997; Gately and 
Howell，1993 and Sood and Buller，1998). 
A variety of cellular functions have been proposed for the causes of cisplatin resistant in 
cells upon prolonged treatment with cisplatin. The cellular functions are metal complex 
accumulation in cells, scavenging of adduct formation with glutathione and 
metallothionein, induction of DNA damage repair, alteration of folate mechanisms, 
changes in oncogene expression and protein kinase activities. Results from many 
studies indicated that these mechanisms in general do not work alone and the resistance is 
generally not governed by one single but multifactors (Asda et al, 1998; Black et al., 
1990; Buller et al, 1997; Cnil et al., 1997; Kay et al., 1997; Kelly and Rozencweig, 1989 
and Welters et aL, 1998). The details for the mechanisms of cisplatin resistance will be 
discussed in the following sections. 
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1.1.4.1 Intracellular Accumulation of Cisplatin 
The total intracellular platinum levels were studied in several cisplatin resistant sublines. 
It has been demonstrated that the cisplatin resistance may be associated with reduced 
intracellular accummulation of the drug (Asda et aL, 1998，Gately and Howell, 1993 and 
Burger et aL, 1998). For example, in human osteosarcoma cell line (OST) and its 
cisplatin subline (OST/R)，the level of platinum in OST cells increased linearly in 
accordance with the time of exposure to cis-diamminedichloroplatinum(II) (CDDP) and 
reached a state of equilibrium at 12 hour. However, accumulation in OST/R cells 
gradually decreased between 8 and 24 hours. The platinum accumulation in OST/R 
cells was 60% of that in OST cells until 4 hours, and 40% after 12 hours. The 
differences in the platinum content between OST and OST/R cells were significant both 
at 12 and 24 hours (p<0.005) (Asada et aL, 1998). The data from another experiment 
showed that the platinum accumulation level in cisplatin resistant 2102 cells was lower 
than the other two sensitive cell lines (NCCIT and S2 cells) (Burger et al., 1998). 
However, there was no alteration in cellular uptake of cisplatin in rat ovarian carcinoma 
cell ROT68 and its cisplatin resistant subline (Kelly and Rozencweig, 1989). Therefore， 
decreased drug accumulation accounts for the drug resistance in cancer cells might be 
cell line dependent. As cisplatin accumulation might be cell line dependent, it would 
also be measured in our study. Other than the decreased platinum accumulation levels 
in drug resistance cells, some other factors might also contribute to the drug resistance 
mechanisms (Chu, 1994; Deepley and Cole, 1997; Gately and Howell, 1993; Hickson 
and Hochhauser, 1997 and Lanzi et aL, 1998). 
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1.1.4.2 Glutathione S-Transferase and Glutathione 
Cisplatin accumulated in cells might be detoxified by conjugation with glutathione in the 
presence of glutathione S-transferase. Glutathione (GSH) and glutathione-S-
transferases (GSTs) are known as drug detoxification agents. They protect cellular 
macromolecules against the attack by reactive electrophiles. According to these 
properties, they play an important role in drug resistance mechanisms (Clapper and Tew, 
1989 and Clapper et al., 1991). 
Glutathione-S-transferases (GSTs; EC 2.5.1.18) are multigene family in mammalian cells. 
It can be grouped into five classes, designated alpha, mu, pi, theta, and microsomal; and 
two types of membrane-bound GST (Board et al., 1990; Di et al., 1987; Meyer et al., 
1990; Mannervik et al., 1987; Puchalski and Fahl, 1990 and Raha and Tew, 1996). The 
expression of various isozymes are tissue specific (Atkins et aL, 1993; Black et al., 1990; 
Buller et aL, 1987; Clapper and Tew, 1989 and Hall et aL, 1994). Since anti-cancer 
drugs are toxic compounds to the cancer cells, GSTs are responsible for the conjugation 
of certain anti-cancer drugs to glutathione. A wide range of studies reported that there is 
an increase in the expression of pi class GST (GSTjt) accompanying the development of 
resistance to many agents including doxorubicin, cisplatin, mitomycin C and melphan 
(Deepley and Cole, 1997 and Hickon and Hochhauser, 1997). The over-expression of 
the GST-Ji has frequently been linked to the MDR phenotype (Howie et al., 1990; 
Jensson et aL, 1987; Sato, 1988 and Tew, 1994). 
Glutathione (GSH), the most ubiquitous and abundant nonprotein thiol, is essential in 
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numerous detoxification reactions and is therefore considered as a chemoprotectant (Chu， 
1994; Raha and Tew, 1996 and Sato, 1989). y-Glutamylcysteinyglycine is a tripeptide 
thiol. In human, the cellular glutathione content varies from 30 ！iM to 3 mM (Raha and 
Tew, 1996). As a potent nucleophile, GSH reacts with alkylating agents and cisplatin. 
The reaction of GSH and cisplatin in a 2:1 molar ratio forms a GSH-platinum complex 
that is then eliminated from the cell by an ATP-dependent glutathione S-conjugate export 
pump (Chu, 1994). 
Direct association between increased GSH and GSTji isozyme levels and cisplatin 
resistance. GSH levels are inversely related with the levels of cisplatin-induced 
cytotoxicity. GSH specifically shown to inhibit the interaction of cisplatin with DNA 
(Kurokawa et al., 1995; Lewis et al, 1988 and Raha and Tew, 1996). The study from 
Ishikawa provides evidence that the glutathione S-conjugate export pump (GS-X pump) 
is functionally over-expressed in cisplatin-resistant human promyelocytic leukemia HL-
60 (HL-60/R-CP) cells, in which the cellular GSH level was substantially enhanced. 
Indeed, the rate of ATP-dependent transport of the GS.Pt complex, measured with plasma 
membrane vesicles, was about 4-fold greater in HL-60/R-CP cells than in HL-60 cells. 
The intracellular GSH level in the resistant cells increased about 7-fold (7.52±0.74 
nmol/lO" cells for HL-60/R-CP cells versus 1.15±0.12nniol/10' cells for HL-60 cells) 
(Ishikawa et al.，1994). Another study from Perez reports that GSH can bind cisplatin in 
cytoplasm or which is monofunctionally bound to DNA. GSH-platinum complexes are 
actively transported out of the cells, which could contribute to cisplatin efflux. This 
would be consistent with the inverse correlation between GSH levels and cisplatin 
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accumulation that observed in spontaneously transformed rat ovarian surface epithelial 
cell lines (Perego et al., 1999). 
Although some reports showed that there is an increased glutathione levels in cisplatin 
resistant cells, but the others are not (Chu, 1994). Welters et al described that the total 
levels of GSH and the expression of GST isoenzymes in the eight head and neck 
squamous cell carcinoma (HNSCC) cell lines cannot explain the cisplatin-induced GSH 
levels (Welters et al., 1998). Another study measured the levels of intracellular 
glutathione of A431 and A431/Pt cells. Significant pharmacologically relevant 
differences (P>0.05) of GSH were not found between sensitive (9.5 ± 0.9 nmol/10^ cells) 
and resistant cells (13.7 士 1.4 nmol/lC/) cells) (Lanzi et al., 1998). There is no alteration 
in cellular glutathione content in rat ovarian carcinoma cell line ROT68 and its cisplatin 
resistant subline; and the U2-0S cisplatin sensitive cells and U2-0S/Pt cisplatin resistant 
cells (Kelly and Rozencweig，1989). Table 2 showed the summary of GSH, GSH-
related enzymes and glutathione S-conjugate export pump (GS-X pump) in drug 
resistance tumor cells (Zhang et al., 1998). Therefore, the association of glutathione 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mammalian metallothionein (MT) is a small protein of 61-62 amino acids that contains 
30% cysteine residues. It has a presumed role in the detoxification of heavy metal ions. 
Multiple inducers of MT synthesis have been identified including heavy metals ions 
glucocorticoids，interferon, and stress and alkylating agents exposure (Chu, 1994 and 
Kelly and Rozecweig, 1989). In some studies, cell lines selected with heavy metals 
showed increases in MT and became cross-resistance to cisplatin. By increasing the 
cellular metallothionein content in the normal tissue, it may be possible to increase the 
therapeutic index of cisplatin (Kelly and Rozecweig，1989). However，selection of cells 
with cisplatin often has no effect on MT. Transaction of mouse C127 cells with a 
metallothionein gene construct yielded inconsistent effects on cisplatin resistance (Chu, 
1994). Therefore，metallothionine might or might not be a factor of cisplatin resistant. 
1.1.4.4 Cell Cycle Perturbation 
Some cell cycle-associated events are believed to be required for the cytotoxicity of 
cisplatin. Inhibition of DNA synthesis and a block in S and GzM-phase of the cell cycle 
are the events for the induction of cell death by cisplatin (Lanzi et al., 1998). 
A protective role against DNA damage has been assigned to the G2M check point. In 
the flow cytometry studies, murine L1210 cells and Chinese hamster ovary (CHO) cells 
were arrested at different phases of GjM upon treatment with different concentrations of 
cisplatin (Keppler, 1993). In other laboratories, cisplatin resistant subline, A431/Pt cells, 
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was derived from A431 cells. Cisplatin treatment however induced G2M arrest in both 
A431 parent and A431/Pt cells. The sensitive and resistant control cell lines progressed 
similarly but with a time delay in A431/Pt cells throughout the cell cycle (Lanzi et al,, 
1998). Such cell cycle perturbation might be one of the reasons for drug resistance 
mechanisms. 
1.1.4.5 P-glycoprotein 
An increased efflux of the drugs may account for the differential chemosensitivity in 
cisplatin resistant cells. P-glycoprotein is an energy-dependent efflux pump that reduces 
the intracellular concentrations of chemotherapeutic agents by transporting them across 
the plasma membrane. It comprises a subset of family proteins within the superfamily 
of ATP Binding Cassette (ABC) transmembrane transporters. The transmembrane 
protein mediates an energy-dependent drug efflux mechanism. It pumps the natural 
product anticancer drugs out. Therefore, the term multi-drug resistant (MDR) has 
become synonymous with the expression of a 170 kDa protein, P-gp (Deeley and Cole, 
1997; Ford et aL, 1996 and Hickson and Hochhauser, 1997). 
In humans, two isoforms of mdr gene have been identified which are named as MDRl 
and MDR2. The multidrug resistance phenotype is usually associated with the 
increased expression of only MDRl (Bookman, 1998 and Ford et al., 1996). 
Overexpression of P-gps (MDRl) characteristically accumulates fewer drugs in the 
selected mammalian multidrug resistant cell lines in vitro (Gelasco and Lippard, 1999 
and Natile and Coluccia, 1999). The overexpression of MDR2 is not common in 
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clinical samples, but it was detected in some cases of chronic lymphocytic leukaemia and 
prolymphocytic leukaemia (Ford et aL, 1996). Though there are 80% structural 
homology between the two isoforms (MDRl and MDR2), there is no evidence that 
MDR2 can confer a multi-drug resistance phenotype (Keim, 1993; Gelasco and Lippard, 
1999 and Deeley and Cole, 1997). Ling and colleges found that the presence of P-gp 
was correlated with both the degree of resistance and the relative decrease in drug 
accumulation. It was suggested that the resistance might be associated with an energy-
dependent mechanism for the decreased accumulation and retention of cytotoxic drugs 
(Deeley and Cole, 1997). 
However, many studies suggested that cisplatin resistance were seldom related to the 
expression of P-glycoprotein. Renal cell carcinoma (RCC8701) and its multi-drug 
resistant cell (RCC8701/ADR800); and neuroblastoma parent cell (BMl) and its cisplatin 
resistant cells (BM1R2) showed no difference in the expression of P-glycoprotein level 
between the parent and its resistant cells (Yausuno et al, 1999 and Yu et al., 2000). 
Furthermore, P-glycoprotein was not expressed in cisplatin resistant KCP-4 cells when 
compared with the parent KB-3-1 cells (Chen et aL, 1999). Although P-glycoprotein 
might not be a common factor for the cisplatin resistance, it is still worth to examine its 
role in the cross-resistance of the cells derived from the experiment. 
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1.1.4.6 Multidrug Resistance Protein (MRP) 
MRP, a 190 kDa multidrug resistant protein, is another protein which is known to be 
coferred to be the ATP-binding cassette (ABC) super family of transport proteins (Oguri 
et al, 2000). It shares only 15% homology to P-gp. However, ATP-dependent binding 
and transport of drugs at relevant concentrations have not yet been demonstrated in 
membrane vesicles from cells that overexpress MRP. There is no direct evidence that 
MRP have the same action mechanism as the P-gp (Cole and Deeley, 1996 and Hickson 
and Hochhauser, 1997). 
MRP is a GS-X pump which is present on vesicles and/or the plasma membrane. Over-
expression of MRP displays different extent of drug accumulation reduction. MRP 
overexpression has been detected in numerous non-P-gp multidrug resistant cell lines. 
These cell lines include small and non small cell lung, breast, prostatic, bladder, and 
cervical cancer cell lines (Bucana et aL, 2000; Cole and Deeley, 1996 and Welters et al., 
1998). 
A number of substrates are transported by MRP after the conjugation to GSH. MRP is 
believed to be responsible for the cisplatin resistance as platinum might be one of the 
substrates for the conjugation to GSH. The ability of MRP to transport heavy metal 
GSH conjugates or complexes is still under investigation. The relationship between 
cisplatin resistance and MRP is still not yet clear (Deeley and Cole, 1997 and Welters et 
al.’ 1998). 
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The efficiency of MRP was different in different cell lines in different studies. Different 
drug-selected cell lines over-expressing MRP display different extent of drug 
accumulation reduction and rate of ATP-dependent drug efflux. Recent report showed 
that the over-expression of MRP is involved in reducing accumulation of cisplatin in 
cisplatin resistant human epidermoid carcinoma cells (Asada et al, 1998). However, 
not all the reports showed the same conclusions. Both lung cancer cell lines and 
peripheral mononuclear cells (PMN) expressed the same levels of MRP5 after the 
exposure of cisplatin (Oguri et al., 2000). Besides, another report showed an inverse 
correlation between MRP and the IC50 of cisplatin in head and neck squamous cell 
carcinoma (HNSCC cells). The GS-X pump activity, i.e. transporting GSH-conjugated 
cisplatin out of cells, may not be the major function of MRP (Welters et al., 1998). 
Hence, these two reports showed that the MRP might not be related to the cisplatin 
resistant. 
The information of MRP is far less been known as that of P-gp and the relationship 
between cisplatin resistance and MRP is still not yet clear. But one is known that 
similar to P-gp, MRP might function as a drug resistance mechanism in certain cell lines. 
1.1.4.7 Topoisomerase 
DNA topoisomerase is also one of the common proteins involved in drug resistance of 
cells. In cells, DNA topology is regulated and controlled by ubiquitous enzymes known 
as topoisomerases, which break and reseal the polyphosphate backbone of the DNA and 
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pass other strands of DNA through the transient gaps (Froelich-Ammon and Osheroff, 
1995; Gupta et al, 1995 and Kay et al., 1997). It is a parameter critical for the 
processes such as replication and transcription. 
DNA topoisomerses are divided into two types, type I topoisomerase (topo I) and type II 
topoisomerase (topo II). Topo I is a 100 kDa protein which can alter the pitch of DNA 
double helices by cutting one DNA strand and allowing passage of the complementary 
strand through the transient nick (Ribin et al., 1996; Hickson and Hochhauser, 1997 and 
Kay et al,, 1997). Topo II has two isozymes, topollcc (170 kDa protein) and topo II|3 
(180 kDa protein), which requires ATP hydrolysis for catalytic activity and alters DNA 
topology by creating transient double strand breaks through which a second intact double 
helix is passed. Topo II was being interested in cancer treatment because it targets on 
the double strand breaks instead of single strand break (Hickson and Hochhauser, 1997 
and Kay et al, 1997). 
Though topo II poisons are effective in anti-cancer treatment, they are not effective in 
certain drug resistant cancer cells. In certain drug resistant cancer cell lines，there are no 
changes in the accumulation or efflux of the topoisomerase II drugs, and the resistance 
might be due to the decreased topo II enzyme activity of cells. Data from several 
reports indicating that tumor cells that are resistant to the anthracyclines (topo II poisons) 
have reduced levels or altered activity of the enzyme with a concomitant reduction in the 
level of drug-associated strand breaks in DNA (or a reduction in DNA-protein cross-link 
formation) (Gewirtz, 1999; Deffie et al., 1989 and Webb et al., 1991). A mutant P388 
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leukemia cell line made doxorubicin resistance (5- to 10-fold) was found to have 
decreased amounts of both topoisomerase II protein and topoisomerase II catalytic 
activity. In Northern and Southern blot analysis, the level of topoisomerase II transcript 
in the mutant was 7- to 8-fold reduced as compared with the parental cell line and the 
copy number of the topoisomerase II gene was also apparently reduced in the mutant 
(Deffie et al., 1989). 
However, reduced topo II levels was seldom related to the cisplatin sensitivity. A 
cisplatin-resistant cell line，SBC-3/CDDP, was established from a human small-cell lung 
cancer cell line, SBC-3. There is an increased level of topoisomerase I acitivity in SBC-
3/CDDP cells (Moritaka et al., 1998). In the osteosarcoma cell system, there is no 
marked difference in the expression of topoisomerase I，Ila and II|3 genes between the 
sensitive and the resistant cells of U2-0S and U2-0S/Pt respectively (Perego et al., 1999). 
The cisplatin resistance mechanism in human transitional cell cancer (TCC) were not 
significantly related to topoiosmerase I and II (Koga et al., 2000). 
1.1.4.8 DNA Repair 
DNA repair can be viewed as contributing factors towards intrinsic tumor cell resistance 
via utilization of enzymes whose primary role is in the repair of DNA damage elicited by 
environmental mutagens and carcinogens. Most agents act via damaging the structure 
of DNA rather than by interfering indirectly with the processing of DNA. It is likely 
that the ability of cells to repair the damaged DNA would be a major factor for the drug 
resistance mechanisms. 
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There are several repair systems in human to protect the genome by repairing modified 
bases，DNA adducts, cross links and double- or single-strand breaks. DNA damages 
can be repaired in the following ways, direct repair of the damaged base, base excision 
repair，nucleotide excision repair, post-replication daughter strand repair, mismatch repair 
and recombinational repair (Crul et al., 1997). 
In some cisplatin resistant cell lines, a number of reports had showed that there were 
some changes in DNA repair efficiency, or the expression of specific DNA repair 
enzymes. Tumor cells which are resistant to cisplatin may have increased capacity to 
recognize and repair drug-induced bidentate intrastand DNA crosslinks. Masuda and 
co-workers demonstrated that there was an increase in repairing DNA damage in a 
cisplatin resistant human ovarian cell line (Kelley and Rozencweig, 1989). In rat 
ovarian carcinoma cell line ROT68/C1 cisplatin subline, the cells demonstrated increased 
unscheduled DNA synthesis after exposure to cisplatin, and it may be a result of 
increased activity of the DNA repair system (Kelly and Rozencweig, 1989). 
A recent report correlated the loss of DNA mismatch repair activity with enhanced 
sensitivity to cisplatin (Reardon et al., 1999). Mismatch repair is also a post-replication 
type of repair. MMR plays a prominent role in the correction of replicative mismatches 
that escape DNA polymerase proofreading. MMR system can recognize and bind to 
various types of adducts in DNA as well as to mismatches. Rather than being a major 
effector of the removal of such adducts, the main role of the MMR seems to be as a 
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detector of specific types of DNA damage. MMR was originally described in bacteria 
that are able to repair mispair-containing bacteriophages. The MMR proteins are highly 
conserved in both prokaryotic and eukaryotic cells. Biochemical and genetic studies in 
human cells have defined five genes. Their gene products hMSH2, hMSH3, and 
hMSH6 [also called GTBP or pl60], the homologues of MutS, and hMLHl and hPMS2， 
play a key role in DNA mismatch repairing (Fink et al., 1998). 
In another hypothesis, the human mismatch repair complex has been shown to recognize 
specifically a single cisplatin G-G intrastrand adduct within a synthetic duplex 
oligonucleotide. It is hypothesized that mismatch repair proteins attempt to insert the 
'correct' base on the non-damaged strand opposite to the adduct. Establishment of such 
a 'futile' repair cycle might then generate a signal triggering apoptosis. According to 
this hypothesis, loss of mismatch repair proteins confers resistance through failure to 
recognize and initiate apoptosis in the response to unrepairable DNA damage. Resistant 
cells thus acquire the ability to tolerate damage that would otherwise be lethal. 
Loss of mismatch repair has been associated with low level of cisplatin resistance in 
cellular models of different tumor type. The expressions of MLHl and MSH2 were 
being examined to establish whether alteration of the mismatch repair machinery could 
be related to the observed increased tolerance to cisplatin-induced DNA damage in the 
studied cell system. MSH2 expression was reduced in A431/Pt cells, whereas MLHl 
level remained unchanged as compared to parental cells (Lanzi et al., 1998). However, 
in the human osteosarcoma cisplatin resistant cell line (U2-0S/Pt), the expression of 
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MSH2 and MLHl were unchanged (Perego et aL, 1999). Since the A431/Pt cells were 
established in a different way as the one that we used in this study, the mismatch repair 
protein was also investigated. 
1.1.4.9 Induction of Programme Cell Death 
The process of programme cell death (apoptosis) reveals DNA fragmentation into 
multimers of 180 base pairs, consistent with internucleosomal cleavage of chromatin by 
an endonuclease, followed by the loss of membrane integrity and cell shrinkage. The 
distinctive DNA degradation pattern of 180-200 bp fragments characterized as DNA 
ladders can be viewed on an agarose gel. When exposing the cells to cisplatin, a greater 
extent of floating cells and DNA fragmentation were formed in the parent cells (A2780) 
than that of the cisplatin resistant cells (A2780cp) (Raaphorst et al, 1998). In another 
experiment, treatment with cisplatin (12.5 |iM) in the vast majority of NT2, NCCIT and 
S2 cells had an apoptotic appearance as judged by the morphological changes, such as 
chromatin condensation, nuclear fragmentation and the appearance of apoptotic bodies. 
In contrast, cisplatin-resistant 2102 EP cells exhibited only about 10% apoptotic nuclei. 
In addition, the time course of apoptosis induction for 2102 EP showed that the apoptotic 
response in this cell line was simply delayed in time. The dose-effect relationship 
between cisplatin concentration and the extent of apoptosis induction further 
demonstrated that 2102 EP cells are resistant to cisplatin-induced apoptosis (Burger et al, 
1998). 
The process of apoptotsis is regulated at least by the gene product of the Bcl-2 family. 
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The Bcl-2 proteins are involved in the control of apoptosis in different cell types and can 
either function as inhibitors (e.g. Bcl-2, Bcl-x, Mcl-l and A l ) or promoters (e.g. Bax， 
Bcl-Xs, Bad and Bak) of cell death. Some of these proteins physically interact with each 
other and form homo- and heterodimers (e.g. Bcl-2/Bcl-2, Bcl-2/Bax and Bax/Bax). It 
was proposed that Bax homodimers promote apoptosis and that the Bax-mediated cell 
death is counteracted by Bcl-2/Bax heterodimerization (Burger et al., 1998). 
Modulation of apoptosis may influence resistance to chemotherapy and therefore affect 
the outcome of cancer treatment. Bcl-2 and p53 were found to be differentially 
expressed in pairs of cisplatin sensitive and resistant ovarian cell lines, with the resistance 
variants naturally over-expressing Bcl-2 (41 McisR and 2780CP cells) as assessed by 
Western blot analysis (Eliopoulos et aL, 1995). Exogenous expression of Bcl-2 in the 
ovarian cell line A2780 resulted in protection from drug-induced apoptosis and a delay in 
drug-mediated S-phase arrest (Eliopoulos et al., 1995). 
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1.2 OBJECTIVES 
Cisplatin is one of the most effective chemotherapeutic agents for cancer patients. 
However, cancer patients who had previously been treated with cisplatin may acquire the 
resistance to cisplatin and other drugs. This is one of the major obstacles in cancer 
chemotherapy. To understand the importance of various cisplatin resistances factors and 
how they interact in cells, a cisplatin resistant cell line (A431/CP500N cells) was 
established from human squamous carcinoma A431 cells. In addition, the parent and 
the cisplatin resistant cells were then compared with various known cisplatin resistance 
factors in term of the expression of drug sensitivity. 
The cisplatin sensitivity of the cisplatin resistant cells was first confirmed by MTT assay. 
Generally speaking, cells which are resistant to one kind of anti-cancer drug might also 
be cross-resistant to some other anti-cancer drugs. In this study, the sensitivity of cells 
to several other anti-cancer drugs was also examined to verify the cross-resistance 
phenomenon in A431 cisplatin resistant cells. 
After that, the cisplatin resistance mechanisms in cells were studied. Since it is believed 
that the cisplatin resistance might be due to multiple factors, the factors examined in 
cisplatin resistant A431 cells were intracellular accumulation of cisplatin, cellular GST 
protein level, GSH，cell cycle distribution, P-glycoprotein levels, topoisomserase, DNA 
damage repair and cisplatin induced apoptosis. 
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1.3 MATERIALS AND METHODS 
1.3.1 Materials 
Chemicals Company 
� 1 0 0 % Dimethyl sulfoxide (DMSO) Sigma 
� l O X Trypsin with EDTA Gibco / Life Technologies, Ltd. 
�2’，7’-Dichlorofluorescin (DCF) Molecular Probe 
�:2-Mercaptoethanol Sigma 
�3-[4,5-Diinethylthiazol-2-yl] Sigma 
-2,5-diphenyl-tetrazolium bromide (MTT) 
�5,5'，6，6，-Tetrachloro-l-l’3，3’- Molecular Probe 
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) 
�5-Pkiorouracil Sigma 
~ 69% Concentrated nitric acid BDH Laboratory Suppliers 
� A c r y l a m i d e / bisacrylamide BIORAD 
� A g a r o s e Gibco / Life Technologies, Ltd. 
� A m m o n i u m persulphate Sigma 
�Aprot in in Boehringer Mannheim 
� B C A protein assay Pierce 
� B C P Molecular Research Centre 
�Bromophenol blue Sigma 
� C a l c i u m chloride Sigma 
~ Camptothecin Calbiochem 
�Chloroform BDH Laboratory Suppliers 
�Cisplat in Sigma 
�Copper(II) sulphate 5H2O Sigma 
� D i e t h y l pyrocarbonate (DEPC) USB 
�Dihydroethidium (HE) Molecular Probe 
�Doxorubicin Sigma 
~ Dulbecco's Modified Eagles's medium (DMEM) Gibco / Life Technologies, Ltd. 
� E C L Western blotting detection reagents Amersham 
� E t h a n o l BDH Laboratory Suppliers 
�Etharyanic acid Sigma 
�Ethidium bromide Sigma 
�Ethylenediaminetetraacetic acid (EDTA) USB 
�Etoposide Sigma 
� F e t a l bovine serum Gibco / Life Technologies, Ltd. 
� G e n e specific primers Gibco / Life Technologies, Ltd. 
�Genistein Calbiochem 
� G l y c e r o l Sigma 
� G l y c i n e Gibco / Life Technologies, Ltd. 
� H i g h range and low range molecular weight standard BIORAD 
~ Isoamyl alcohol Sigma 
�Isopropanol BDH Laboratory Suppliers 
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�Leupectin Boehringer Mannheim 
�L-glutamine Gibco / Life Technologies, Ltd. 
~ Magnesium chloride Sigma 
~ Metaphosphoric acid Sigma 
~ Methanol BDH Laboratory Suppliers 
~ Methotrexate Sigma 
�N,N，N'，N'-tetramethylethylenecliamine (TEMED) BIORAD 
� O l i g o - d T primers Gibco / Life Technologies, Ltd. 
� P h e n o l USB 
�Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
�Phosphate buffered saline (PBS) Gibco / Life Technologies, Ltd. 
�Polyoxyethylenesorbitan monolaurate (Tween 20) Sigma 
�Propidium iodide Sigma 
� P r o t d m s c K Sigma 
� R e v e r s e transcriptase Gibco / Life Technologies，Ltd. 
~ RNase A Sigma 
� S o d i u m acetate Sigma 
� S o d i u m chloride USB 
~ Sodium diphosphate Sigma 
~ Sodium Dodecyl Sulfate (SDS) Gibco / Life Technologies, Ltd. 
� S o d i u m orthovanadate Sigma 
~ Taxol Sigma 
�Thimersol Sigma 
�TRI-reagent Molecular Research Centre 
�Tris-base USB 
�Tris-HCl Gibco / Life Technologies, Ltd. 
~ Triton X-100 Boehringer Mannheim 
~ Vincristine Sigma 
Antibodies Company 
~ Anti-Bcl-2 Santa Cruz 
�Anti-Bcl-Xi Santa Cruz 
~ Anti-Fas Santa Cruz 
�Anti-Fas Ligand Santa Cruz 
�Anti-Glutathione S-transferase Crystal Chem 
~ Anti-P-glycoprotein Oncogene 
�Horseradish peroxidase conjugated secondary antibody (Goat) Santa Cruz 
�Horseradish peroxidase conjugated secondary antibody (Mouse) Amersham 
�Horseradish peroxidase conjugated secondary antibody (Rabbit) Amersham 
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Culture wares Company 
� 2 5 cm^ and 75 cm^ culture flask Corning / Falcon 
� 6 0 mm and 100 mm culture dish Coming / Falcon 
~ 96-well flat-bottom culture plate Coming / Falcon 
Instruments Company 
� F A C S O R T flow cytomter Becton Dickinson 
� F i l m cassette Kodak 
�Immobilon-P transfer membrane Millipore 
�Microplate reader Molecular Device 
�Mini-PROTEAN®II electrophoresis apparatus BIORAD 
�Thermal Cycler 9700 Perkin Elmer 
� T h i c k blotter paper Falcon 
�Trans-Blot® SD semi-transfer cell BIORAD 
� U V transilluminator UVP 
� X - r a y s film Kodak / Fuji 
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1.3.2 METHODS 
1.3.2.1 Cell Lines 
Human squamous carcinoma A431 cells, and its sublines were cultured in Dulbecco 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 5 
mM L-glutamine in 3 7 � C humidified 10% CO] incubator. 
Establishment of Cisplatin Resistant Cells Lines (A431/CP500N) 
80% Confluent A431/P cells in a 75 cm" culture flask were treated with 100 \xg/m\ 
cisplatin. Fresh medium was replaced after 1 hour incubation of cisplatin. The cells 
were cultured to confluent again, and the cells selected were named as A431/CP100N 
cells which were resistant to 100 \xg/m\ cisplatin for 1 hour. Further selection on the 
resistant cells was obtained by increasing the concentration of cisplatin from 100 \xg/m\ 
to 250 [xg/m\ on the A431/CP100N cells. The selected cells were named as 
A431/CP250N cells. Finally, A431/CP500N cells were obtained by treating 
A431/CP250N cells with 500 \xg/m\ cisplatin for 1 hour. These A431/CP500N cells 
would be used as cisplatin resistant cell model in the following chapters. 
1.3.2.2 Drug Sensitivity Assay 
The effect of chemotherapeutic agents on the growth of the cells was determined by MTT 
assay. A431/P (6x10") and CP500N (2xl0') cells were seeded in a 96-well flat bottom 
plates for 2 days to reach the exponential phase. Various concentration of anti-cancer 
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drugs and inhibitors (cisplatin, doxorubicin, genistein，camptothecin, etoposide, taxol, 
vincristine, 5-fluorouracil, methotrexate, etharyanic acid) and Y-irradiation were 
administrated. After 5 days incubation, medium was removed, and 50 i^l of 1 mg/ml 
MTT solution in IX PBS was added. After incubation at 3 7 � C for 3 to 4 hours，dark 
blue formazan was formed and was dissolved in 150 \xl dimethyl sulphoxide (DMSO) for 
30 to 40 minutes at room temperature. Absorbance was read at 570 nm with a 
microplate reader. The sensitivity of the cells to the drugs was calculated by the 
following formula. 
% Survival = Absorbance of with treatment / Absorbance of the control cells x 100% 
1.3.2.3 Platinum Uptake 
Exponentially growing cells were treated with 80 [ig/m\ and 150 \xg/m\ cisplatin for 4 h. 
Cells were harvested by trypsinization and washed with IX PBS. Equal number of cells 
in each treatment was digested in a minimum amount of concentrated nitric acid. The 
platinum accumulation was then measured by atomic absorption spectrophotometer. 
1.3.2.4 Cell Cycle Analysis 
Cells were seeded into a 60 mm petri-dish. The exponentially growing cells were 
treated with different concentration of drugs for up to 2 days. Thereafter, cells were 
harvested by trypsinizaton, washed with ice-cold PBS and fixed with 70% ethanol at 4 � C 
overnight. 
Ethanol was removed by centrifugation at 2500 rpm for 2 minutes. The cell pellet was 
washed with 1 ml ice-cold PBS twice and resuspensed in the staining solution containing 
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0.1% Triton X-100, 0.1 mM EDTA in IX PBS with 80 j^ g/ml RNase A and 40 \xg/ml 
propidium iodide at room temperature for 30 minutes. Cell cycle distribution was 
analysed by FACSort® flow cytometer using FL2-H bandpass filter for propidium iodide 
detection. 
1.3.2.5 Western Blot Analysis 
Preparation of protein sample 
Cells were seeded in a 60 mm petri-dish. After 80% confluence, cells were lysed in 
Lammaeli's buffer containing 21 jig/ml aprotinin, 0.5 ！ig/ml leupeptin, 4.9 mM MgCl], 1 
mM sodium ortho-vanadate, 1% triton X-100 and 1 mM PMSF in IX PBS. Cells were 
scraped by cell lifter. The cell lysate was collected in a 1.5 ml microfuge tube and 
centrifuged at 14000 rpm for 7 minutes at 4°C. 0.5 \x\ of the supernatant of the cell 
lysate was aliquoted (triplicate) for quantification of the protein by the protein assay. 
The supernatant was transferred to a new and clean microfuge tube with the additional of 
equal volume 2X SDS sample buffer (0.125 M Tris base, 20% w/v glycerol, 10% 2-
mercaptoethanol, 4.6% SDS and bromophenol blue, pH6.8). The protein collected from 
the supernatant of the cell lysate was denatured by boiling for 10 minutes. The protein 
samples were kept at —80°C until further analysis. 
Resolution of the protein and transference of the protein to a PVDF membrane 
30-50 fxg proteins were resolved in polyacrylamide gel electrophoresis. The stacking 
and resolving gels were 4.5%/8% and 4.5%/12% respectively for protein with high 
molecular weight range and low molecular weight range respectively. The resolving gel 
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were prepared by mixing appropriate amount of acrylamide / bisacrylamide with 
N,N,N',N'-tetramethylethylenediamine (TEMED) and 0.05% ammonium persulphate in 
IX Lower gel buffer (0.375 M Tris base, 0.1% SDS，pH8.8). The stacking gels were 
prepared by mixing appropriate amount of acrylamide / bisacrylamide with TEMED and 
0.075% ammonium persulphate in IX upper gel buffer (0.125 M Tris-base and 0.1% SDS, 
pH6.8). The gels were set in the Mini-PROTEAN® II gel electrophoresis apparatus. 
All the protein samples were diluted with IX SDS sample buffer (62.5 mM Tris-base, 
10% w/v glycerol, 10% 2-mercaptoethanol, 2.3% SDS and bromophenol blue, pH6.8) to 
the same final protein concentration before loading. The diluted samples were loaded 
onto the gel and run in IX SDS running buffer (25 mM Tris-base, 0.19 M glycine and 
0.1% SDS, pH6.8) at 200 V for 40 minutes. High range and low range molecular 
weight prestained standards were used as marker for 8% and 12% gels respectively. 
Protein transfer 
After the proteins were resolved, the gel was removed from the apparatus for 
electroblotting. Firstly, thick blotter papers were soaked in electroblot transfer buffer 
(25 mM Tris base, (3.19 M glycine and 15% methanol) and onto the platinum anode of the 
TransBlot® SD Semi-Dry Transfer Cell. Then immobilon-P transfer membrane was 
wet in 100% methanol for 1-2 seconds and equilibrated in the electroblot transfer buffer 
for 5 minutes. The equilibrated membrane was placed on the blotter paper. 
Subsequently, the gel was rinsed with the electroblot transfer buffer and placed to the top 
of the membrane. Another piece of blotter paper was pre-soaked in electroblot transfer 
buffer, placed onto the gel and the stainless steel cathode w.ts placed onto the stack. The 
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resolved proteins were transferred from the gel to the membrane for 30 minutes at 15 V 
and the blotted membrane was used for antibody probing. 
Immumnoblotting 
The membranes were immersed in 100% ethanol for 10 seconds and washed with PBS 
for 1-2 seconds. The membranes were blocked with 5% non-fat milk in a square petri-
dish at 4 � C overnight. The unbound milk was washed away with IX PBS with 0.1% 
Tween 20 for 15 minutes three times. The membranes were then incubated with the 
corresponding primary anti-body (GST; P-glycoprotein; Topoisomerase II; Bcl-2; Bcl-xL; 
Fas; Cas; Tiar; Fas Ligand) for 2 h with continuous shaking. The unbound primary anti-
body was washed away by IX PBS with 0.1 % Tween 20 three times for 10 minutes. 
Subsequently, the membranes were incubated with horse-radish peroxidase conjugated 
secondary antibody for 1 h with continuous shaking. The unbounded secondary anti-
body was washed away with IX PBS - Tween 20 for 15 minutes three times. The 
signals were detected by enhanced chemiluminescence (ECL). 2 ml of ECL Western 
Blotting Detection Reagent 1 and 2 were mixed in a square petri-dish. The washed 
membranes were placed into the mixed reagent and incubated for 1 minutes. The 
membranes were then wrapped in a ceramic-wrap and air bubbles were smoothed out. 
Finally, the membrane with the protein side up was placed into film cassette and the 
signal was detected by the exposure to the X-ray film. 
Protein assay 
0.5 \x\ of the protein sample from the supernatant of the cell lysate was aliquoted onto a 
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96-well flat bottom plate in triplicate. BSA at different concentrations was used to 
generate a standard curve for the protein sample. After mixing 9.8 ml BCA (solution A) 
with 0.2 ml copper (II) sulphate (solution B)，0.2 ml of the solution was added into each 
well of the 96-well plate and incubated for 30 minutes at 37°C for the color development. 
Absorbance was read at 540 nm. The concentration of the protein in the cell lysate was 
calculated by the protein standard curve from BSA. 
1.3.2.6 Glutathione Content Determination 
Cells were grown to 80% confluence in a 100mm petri-dish. Cells were trypsinized and 
equal number of cells was sonicated. 0.75 ml of precipitating solution (disodium EDTA; 
NaCl and metaphosphoric acid) was added to the cells for 10 min to precipitate the 
protein. After centrifugation at 4000 rpm for 10 min, the supernatant was removed and 
then neutralized by 2 ml of 0.3M Na^HPO*. 0.25 ml of 0.02% DTNB was then added to 
the solution for colour development. Absorbance was read at 412 nm. 
1.3.2.7 DNA Fragmentation 
Exponentially growing cells in a 60 mm culture dish were treated with different 
concentration of anti-cancer drugs (cisplatin, doxorubicin, 5-fluorouracil, vincristine and 
taxol) for 2 or 3 days. Cells were harvested by trypsinization and lysed in 0.5 ml lysis 
buffer (5 mM Tris-HCl; 100 mM EDTA (pH8.0); 1% SDS; 0.4 jig/ml proteinase K) at 
37°C overnight for digestion. The DNA was extracted in 0.5 ml phenol following with 
0.5 ml chlorofonn:isoamyl alcohol (24:1), vortexed vigorously and centrifuged at 10000 
rpm for 2 minutes. The supernatant was transferred to a new 1.5 ml microfuge tube 
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which contained 0.5 ml chloroform:isoamyl alcohol (24:1). DNA was precipitated in 50 
pi 3 M sodium acetate and 1 ml absolute ethanol overnight at -20°C. 
DNA pellet was collected by centrifugation at 14000 rpm for 30 minutes by removing the 
supernatant and was then air-dried. The DNA pellet was dissolved in TE buffer (10 mM 
Tris-HCl and 0.5 mM EDTA, pH8.0) with 0.4 mg/ml RNase A. 
The concentration of DNA was quantitated by reading the absorbance at OD 260 and OD 
280 nm. 60 \xg of DNA was then applied to 1.5% (w/v) agarose gel in IX TBE buffer 
(0.089 M Tris base, 0.089 M boric acid and 2 mM EDTA, pH8.0), separated by 
electrophoresis, and visualized by staining with 0.05 [ig/ml ethidium bromide under an 
UV transilluminlator. 
1.3.2.8 JC-1 Staining 
Exponentially growing cells were treated with different concentrations of anti-cancer 
drugs (cisplatin, doxorubicin, 5-fluorouracil and vincristine) for 2 days. Cells were 
harvested by trypsinization and washed with IX ice-cold PBS. 5x10^ cells were 
resuspensed with ice-cold phenol red free, serum free DMEM, and stained with 10 \xM 
JC-1 for 15 min at 3TC incubator before flow cytometric analysis. The JC-1 exists in 
monomeric (J-monomer) and aggregate (J-aggregate) forms which exhibit an 
fluorescence emission maximal at 527 nm (green) and 590 nm (red) respectively when 
excited at 488 nm. 
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1.3.2.9 HE and DCF Staining 
The intracellular formation of H^O: was quantitated by the diacetate form of 
dichlorofluorescin (DCF-DA) in flow cytometry. The cellular H2O2 converts the non-
fluorescent dye into fluorescent (DCF) which can be detected by flow cytometry with 
488 nm and 530 nm as the excitation and emission wavelength respectively. 
On the other hand, the formation of superoxide (CV) was detected by hydroethidium 
(HE). The cellular superoxide oxidized the HE to produce ethidium bromide. 
Ethidium bromide intercalates into the DNA and gives out fluorescent which can be 
detected by flow cytometry with 488 nm and 616 nm as the excitation and emission 
wavelength respectively. 
Cells were prepared as described in JC-1 staining. The cells were stained with 10 i^M 
HE or 10 [xM DCF and PI for 30 min at room temperature at the dark and then taken for 
flow cytometric analysis. 
1.3.2.10 Quantitative RT-PCR 
Preparation ofRNA 
Cells were grown to 80% confluence in a 100 mm petri-dish. Medium was removed 
and cells were lysed with 1 ml TRI-reagent. The lysate was stored at room temperature 
for 5 minutes in a 1.5 ml microfuge tube to permit the complete dissociation of 
nucleoprotein complexes. 0.1 ml BCP (l-bromo-3-chloropropane) was added and the 
mixture was shaked vigorously for protein extraction. The soluble RNA would be 
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found in the supernatant after centrifugation at 12000 g for 15 minutes at 4°C. The 
aqueous RNA layer was transferred into a new and clean microfuge tube. RNA was 
precipitated by adding 0.5 ml 100% isopropanol with vigorously shaking and then stored 
at room temperature for 5-10 minutes to allow the precipitation of RNA. RNA pellet 
was collected by centrifugation at 10000 g -12000 g for 7 minutes at 4 � C . After the 
removal of isopropanol supernatant, the RNA pellet was air-dried at room temperature 
for 15 minutes. RNA pellet was dissolved in 30 [xl DEPC-treated water at 55°C - 60°C 
for 10 minutes. The RNA samples were kept at _80�C for further analysis. 
RT-PCR 
cDNA was synthesized using oligo dT primer with Superscript RNase H-reverse 
transcriptase. Reverse-transcribed cDNA from each sample was amplified by 
polymerase chain reaction (PGR) using corresponding primers. Amplification was 
carried out using a thermal cycler 9700 in the following conditions: denaturation at 9 4 � C 
for 30 sec, annealing at 40-60�C for 40 sec and extension at 7 2 � C for 30 sec to 1 minute 
or more, followed by incubation at 7 2 � C for 5 min. The PGR products were resolved on 
1.5% (w/v) agarose gels by electrophoresis. DNA was stained with ethidium bromide 
and visualized under an UV-tranilluminator. 
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1.4 RESULT 
1.4.1 Cisplatin Sensitivity of A431 Ceils by MTT Assay 
Although A431/CP500N cells were derived from the parent cells with cisplatin treatment, 
it is still necessary to confirm the cisplatin resistance of the subline. The drug 
sensitivity of cells was assessed by MTT assay and the data is shown in Figure 5a. 
Results shown that A431/CP500N cells were more resistant to cisplatin than the parent 
cells. The IC^ o for cisplatin sensitivity of A431/P cells is 0.1 pig/ml while it is 0.2 fxg/ml 
for CP500N cells. 
1.4.2 Cross-resistance to Anticancer Drugs 
As suggested by many reports, if a cell line is resistant to a kind of anti-cancer drug, it 
would also likely be cross-resistant to other anti-cancer drugs (Ma et al., 1998; Belvedere 
et al., 1996; Takeshita et al, 1996 and Ireland et aL, 1994). For example, the cisplatin 
resistant subline of human ovarian adenocarcinoma cell line (IGROV-1) was strongly 
cross-resistance to doxorubicin, etoposide，5-fluorouracil and methotrexate (Ma et al., 
1998). Several anti-cancer drugs (doxorubicin, genistein, camptothecin, etoposide, taxol, 
vincristine, 5-fluorouracil and methotrexate) and the treatment of 丫-irradiation were used 
to compare the sensitivity pattern between A431/P and CP500N cells. The results were 
shown in Figure 5. The pattern of drug sensitivity can be divided into two categories, 
namely the cross-resistance to other drugs and the shared similar response to the drugs as 
the parent cells (Table 3). As shown in Figure 5b，it was found that CP500N cells were 
more resistant than A431/P cells to doxorubicin. However, there is no difference in the 
IC50 in both A431/P and CP500N cells. The differences in doxorubicin sensitivity 
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between the two cell lines were found at a higher concentration (>0.02 \xg/m\). In figure 
5c，the IC50 of genistein on the parent cells and cisplatin resistant cells is 20 \xM and 34 
fxM, respectively. The result of camptothecin was shown in Figure 5d. The IC50 of 
camptothecin on the cisplatin resistant cells (1匸5()=0.01 i^M) is about two times higher 
than that on the parent cells (IC5()=0.005 i^M). Similar to camptothecin, the IC50 of 
etoposide and taxol for CP500N cells was also about 2 times higher than that of the 
A431/P cells (Fig. 5e and f). For the parent cells, the IC50 of etoposide and taxol is 0.3 
HM and 0.00075 fxg/ml, respectively. For the A431/CP500N cells, the IC50 of etoposide 
and taxol is 0.6 \xM and 0.0016 (ig/ml, respectively. The IQo of methotrexate is slightly 
higher in CP500N cells than the parent cells (Fig. 5g). 
In the case of vincristine, 丫-irradiation and 5-fliiorouracil treatment, the response of 
CP500N cells was similar to the A431/P cells (Fig. 5h, i and j). 
In addition to cisplatin, CP500N cells were also cross-resistance to some other anti-
cancer drugs. In the following sections, the results of some of the anti-cancer drugs 
(cisplatin, doxorubicin，taxol, vincristine or 5-fluorouracil) on the two cell lines will be 
presented. 
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Figure 5. The response of A431 cells to cisplatin and other anti-cancer drugs as 
measured by MTT assay. 
O : A431/P cells 
V:A431/CP500N cells. 
error bar: standard deviation from more than three different experiments. 
Table 3. The sensitivity of A431 cells to different anti-cancer drugs. 
I. Drug that shown cross resistance 
Doxorubicin (Fig. 3b) 
Genistine (Fig. 3c) 
Camptotheicin (Fig. 3d) 
Etoposide (Fig. 3e) 
Taxol (Fig. 3f) 
Methotrexate (Fig. 3g) 
II. Drug that shown no difference/slightly difference in response 
Vincristine (Fig. 3h) 
y-irradiation (Fig. 3i) 
5-Fluorouracil (Fig. 3j) 
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1.4.3 Quantitation of Cisplatin Accumulation in A431 cells by Atomic 
Absorption Spectrophometer 
One of the possible mechanisms for cisplatin resistance is the drug accumulation in the 
cells. The platinum accumulation was measured by atomic absorption 
spectrophotometer (Fig. 6). From the result, the accumulation level in A431/P cells was 
higher than that in the CP500N cells. Hence, the decreased cisplatin accumulation level 
might be one of the mechanisms responsible for cisplatin resistant in CP500N cells. 
. . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . 
I ? — 
80 150 
lag/ml 
Figure 6. The platinum accumulation levels in A431 cells. It was detected by 
atomic absorption spectrophotmeter after the treatment of 80 and 150 jig/ml 
cisplatin for 4 h. 
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1.4.4 Drug Detoxification Agent 
Glutathione and glutathione-S-transferase were considered as chemoprotectants. They 
were known as detoxification agents. The cellular glutathione content in A431/P cells 
and CP500N cells are 38.36±8.26 mmoles/lO' cells and 28.93±7.83 mmoles/10' cells 
respectively (Fig. 7). The results show that cellular glutathione level in parent cells is 
significantly higher (p<0.05) than that in the resistant cells. Hence, cisplatin resistance 
in CP500N cells will unlikely be related to the cellular glutathione level as otherwise it 
will be in a reversed order. The protein level of GST-jt was determined by Western blot 
analysis (Fig. 8a). The level of GST-jt has no difference between the two cell lines. 
By means of GST inhibitor (etharyanic acid), the sensitivities to ethacryanic acid were 
the similar in both cell lines (Fig. 8b). Both results suggested that the cisplatin 
resistance in CP500N cells may be independent of GST-ji level in cells. 
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Figure 7. The intracellular glutathione content in A431 cells. 
Error bar: standard deviation from three different experiments. 
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Figure 8. The GST protein and response to etharyanic acid in A431 cells, 
(a) The GST protein level in A431 cells as detected by Western blot analysis. 
(b) The response of A431 cells to etharyanic acid as measured by MTT assay. 
O : A431/P cells 
V:A431/CP500N cells. 
error bar: standard deviation from more than three different experiments. 
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1.4.5 Detection of Cell Cycle Arrest by Flow Cytometer 
The arrestment of G2M phase in cell cycle has been reported in cells after the treatment of 
cisplatin (Lanzi et aL, 1998). The cell cycle distribution after the treatment with 1 
x^g/ml cisplatin for 12 h，24 h, 36 h and 48 h was shown in Figure 9. There is an 
induction of G2M phase arrest at 12 h in both cell lines in which the parent cells have 
similar responses to cisplatin treatment. The arrestment was released after prolonged 
incubation of cisplatin. 
12 h 24 h 36 h 48 h 
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Fig.9: The cell cycle distribution of cells after treatment of 1 )Lig/ml cisplatin. 
• : Untreated cells. 
• : Cells treated with cisplatin. 
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1.4.6 Expression of Drug Resistance Related Genes 
P-glycoprotein is another common factor known to contribute to drug resistance in cells. 
The P-glycoprotein level was detected by Western blot analysis (Fig. 10a). The P-
glycoprotein level was higher in A431/P cells than that of the cisplatin resistant cells 
(CP500N cells). For the response to verapamil (P-glycoprotein inhibitor), CP500N cells 
were more resistant than the parent cells (Fig. 10b). 
MRP might be another possible mechanism for cisplatin resistance as suggested in some 
reports. The mRNA level of MRP was detected by quantitative RT-PCR, G3DH was used 
as the internal standard to quantitate the mRNA expression level (Fig. 11a). There is no 
significant difference in the expression of MRP between A431/P and CP500N cells. 
Topoisomerase II was responsible for DNA binding, replication and cleavage. The 
higher the topo II level, the least the resistance. In Figure l ib , there was no difference 
in the topo II protein expression levels in both cell lines as assessed by Western blot 
analysis. 
Loss of mismatch repair may contribute to cisplatin resistance in some cells. The 
mismatch repair protein (MSH2) was being analyzed by Western blot analysis and the 
protein level is higher in A431/P than CP500N cells (Fig. lib). 
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Figure 10. P-glycoprotein expression and response to verapamil in A431 cells. 
(a) The P-glycoprotein level in A431 cells as detected by Western blot analysis. 
(b) The response of A431 cells to verapamil as measured by MTT assay. 
0 : A 4 3 1 / P cells 
V:A431/CP500N cells. 
error bar: standard deviation from three different experiments. 
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Primers for MRP: Primers for G3DH: 
Forward: 5'-AGAACCTCAGTGTCGGGCAGCG-3 ‘ Forward: 5’-ACCACAGTCCATGCCATCAC-3， 
Reverse: 5'-TCGCATCTCTGTCTCTCCTGGG-3' Reverse: 5,-TCCACCACCCTGTTGCTGTA-3, 
Figure 11. Expression of drug resistance related genes in A431 cells. 
(a) The mRNA level of MRP as detected by quantitative RT-PCR. G3DH is an 
internal standard to confirm the equal loading of samples. 
(b) The topoisomerase II and MSH2 protein expression level as detected by Western 
blot analysis. 
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1.4,7 Detection of Apoptosis by DNA Fragmentation 
Anti-cancer drugs can affect the cell survival of cells in many ways. One of the most 
common mechanisms is the induction of apoptosis. The formation of DNA 
fragmentation (DNA laddering) is one of the classical features for apoptosis. Under the 
treatment of doxorubicin, cisplatin and taxol, the formation of DNA fragmentation in 
A431/P cells was more significant than that in the CP500N cells (Fig. 12a and b). For 
the vincristine treatment, there is no significant difference in the ladder formation 
between the parent and cisplatin resistant cells (Fig. 12c). However, for the treatment of 
5-fluorouracil, the formation of DNA fragmentation in CP500N cells was slightly less 
than that in the parent cells (Fig. 12d). All the results showed that the higher the 
concentration of the anti-cancer drug, the greater the intensity of DNA laddering 
formation. The extent of apoptosis is in a dose dependent manner. The data except for 
5-fluorouracil from the DNA fragmentation assay in general correlates with the results 
from the MTT drug sensitivity assay. 
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1.4.8 Role of Mitochondria and Reactive Oxygen Species by Flow 
Cytometry 
Some anti-cancer drugs induce apoptosis by the alteration of mitochondrial structure and 
potential. A fluorescence dye JC-1 was used for the analysis of mitochondrial mass 
(JC-1 monomers, FLl-H) and mitochondrial transmembrane potential (J aggregates, FL3-
H). Mitochondrial depolarization was detected by the decrease in the fluorescent 
intensity of JC-1 aggregate together with the increase in the fluorescent intensity of JC-
monomer. To quantitate the extent of mitochondrial depolarization, the population of 
cells was divided into two (right hand side and left hand side) of which the cutoff is at 
channel 100 of JC-monomer fluorescent profile. By comparing the percentage of cells 
in the right hand side and left hand side of the fluorescent profile, the extent of 
mitochondrial depolarization can then be compared. The grerater the percentage in the 
right hand side，the greater extent of the mitochondrial membrane depolarized. 
Under the treatment of 1 fAg/ml cisplatin for 48 h，mitochondrial depolarization was 
detected in parent cells but not in CP500N cells. The effect is similar when the cells 
were treated with taxol. For the treatment with doxorubicin, 5-fluorouracil and 
vincristine, mitochondrial depolarization was detected in both cells. Furthermore, it 
appeared that the extent of drug induced mitochondrial depolarization was higher in 
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Figure 13. The mitochondrial depolorization in A431 cells as stained 
by JC-1 dye after the treatment of (a) cisplatin; (b) doxorubicin; 5-
fluorouracil; vincristine and taxol for 48 h. 
LHS: Percentage of cells in left hand side. 
RHS: Percentage of cells in right hand side. 
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Mitochondrion is one of the major sites of reactive oxygen species (ROS) formation in 
cells and it is suggested to play a central role in the regulation of apoptosis. Formation 
of ROS might be one of the molecular mechanisms of anti-cancer drugs induced 
cytotoxicity in cells. Under the treatment of cisplatin, the shift of the HE fluorescent 
profile in A431/P cells was more than that in the CP500N cells (Fig. 14A). Cisplatin 
induced superoxide formation in A431/P cells but not in the CP500N cells and so was 
taxol treatment. However, for the treatment of doxorubicin, vincristine and 5-
fluorouracil, the formation of superoxide in CP500N cells was more significant as 
compared with the control cells. In the case of peroxide ions, all the 4 drugs did not 
induce peroxide formation in both A431 parent and cisplatin resistant cells, as determined 
by the fluorescent profile of cells stained with DCF (Fig. 14B). 
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Figure 14: The (A) superoxide and (B) hydrogen peroxide formation in A431 cells as 
stained by HE and DCF dye respectively after 48 h treatment of corresponding anti-
cancer drugs as detected by flow cytometer. 
CI: Untreated cells. 
• : Cells treated with anti-cancer drugs. 
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1.4.9 Detection of Apopotic Protein by Quantitative RT-PCR 
The expression of Bd-2 mRNA level was higher in the A431/P cells, while there was no 
significant difference in the expression of Fas and Bc 1 - X l . The mRNA levels of G3DH 
were used as an internal standard of quantitative RT-PCR (Fig. 15a). 
1.4.10 Detection of Apopotic Protein Level by Western Blot Analysis 
Results from MTT assay (Fig. 5) and DNA fragmentation assay (Fig. 12) indicated the 
cisplatin resistance may be related to drug induced apoptosis. Therefore, it is of interest 
to find out the expression levels of various apoptotic proteins in the parent and cisplatin 
resistant cells by Western blot analysis. The protein levels of Bcl-2 in A431/P cells 
were higher than CP500N cells and so as Fas; while A431/CP500N cells had a higher 
expression of Bcl-X^ than the parent cells. By the way，the levels of Fas ligand showed 
no difference between the two cell lines. 
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(a) Quantitative RT-PCR 
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Bcl-2 Fas Bc I -X l G3DH 
(173 bp) (278 bp) (276 bp) (451 bp) 
Primers for Bcl-2: Primers for Bcl-x丁: 
Forward: 5'-CACCAAGAAAGCAGGAAA-3， Forward: 5'-GGTATTGGTGAGTCGGATCG-3， 
Reverse: 5'-CAGGATAGCAGCAC-3' Reverse: 5'-ATGTGGTGGAGCAGAGAAGG-3' 
Primers for Fas: Primers for G3DH: 
Forward: 5'-AAGGAGTACACAGACAAAGCCC-3 ‘ Forward: 5'-ACCACAGTCCATGCCATCAC-3 ‘ 
Reverse: 5'-AAGAAGAAGACAAAGCCACCC-3' Reverse: 5'-TCCACCACCCTGTTGCTGTA-3‘ 
(b) Western blot analysis 
P N P N P N P N 
• •• • 應 
Bcl-2 Fas BcI-X l Fas ligand 
(26 kDa) (45 kDa) (26 kDa) (37 kDa) 
Figure 15. The apoptotic protein levels in A431 cells as detected by (a) 
quantitative RT-PCR and (b) Western blot analysis. 




Cisplatin is an effective chemotherapeutic agent for cancer patients. However，in cancer 
patients who have been previously treated with cisplatin, the efficacy of additional 
cisplatin therapy often decreases, since the tumor has frequently acquired resistance to 
this drug (Mese et al., 1998). In order to study the cisplatin resistance mechanism, a 
cisplatin resistant cell line has been derived from A431 cells. The cisplatin resistance of 
CP500N cells was confirmed by MTT assay (Fig. 5a). In addition to cisplatin, CP500N 
cells were also cross-resistance to some of the other anti-cancer drugs, e.g. doxorubicin, 
but not all of them, e.g. 5-fluorouracil. The cross-resistance pattern in general agreed 
with the pattern as described in other cisplatin resistance cell lines (Ma et al., 1998; 
Belvedere et al., 1996; Takeshita et al., 1996 and Ireland et al., 1994). In term of 
cisplatin resistance mechanisms, the data from the study suggested it would be multi-
factorial in nature. It is consistent with results as reported in other cell systems (Sood 
and Buller, 1998, Mese et al., 1998，Mack et al and Perego, 1999). 
Decreased drug accumulation has been shown to be one of the major contribution factors 
to cisplatin resistance in cells (Mese et al., 1998 and Mack et al., 1997). The lower the 
platinum level accumulated in cells，the higher the resistance of cells. By atomic 
absorption spectrophotometer, the platinum uptake level in the parent cells is higher than 
that in the CP500N cells (Fig. 6). The difference in drug accumulation between parent 
and drug resistance cells is about 2 times and 3 times with 80 ！ig/ml and 150 i^g/ml 
cisplatin treatment respectively. The result from MTT assay (Fig. 5a) showed that the 
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sensitivity of the parent cells to 0.2 fxg/ml cisplatin would more or less be the same as the 
CP500N cells treated with 1 i^g/ml cisplatin which is five times more sensitive than 
CP500N cells. This phenomenon explained that the drug accumulation factor would 
only be one of the important but not the sole factor contributed to cisplatin resistance in 
CP500N cells. 
A positive correction between cisplatin resistance and the elevated GSH or GST levels 
was not observed in this study (Fig. 7 and 8). Even though these two factors have been 
known to be important for cisplatin resistance in certain cell lines, they do not contribute 
to the resistance in our cell system (Bader et aL, 1998; Hayes and Wolf, 1997; Tew, 1994; 
Chu, 1994; Hait, 1996 and Perez, 1998). Other factors confirmed to be not important in 
cisplatin resistance in CP500N cells are topoisomerase II and MRP as their expression 
are similar between the A431 parent and CP500N cells (Fig. 11). The expression of P-
gp is higher in A431/P cells, and the expansion is inversely correlated with the drug 
resistance phenotype (Fig. 10). Similar observations have also been reported previously 
(Kawai et al., 2000 and Ishikawa et al., 1994). In other cell lines, over-expression of 
these proteins were found to correlate with cisplatin resistance in cells (Lincke et aL, 
1991; Van der Bliek et al, 1998; Chin et al., 1989 and Osheroff et aL, 1995). The 
results from the expression of the detoxification agents and the drug resistance related 
genes explained the cisplatin resistance in CP500N cells was not due to the above factors. 
It is conceivable that changes in cellular pathways regulating DNA damage recognition 
and/or cell death may account for the increased tolerance to the drugs (Crul et al., 1997). 
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In this regard, the results showed a correlation between the cisplatin resistance and the 
expression of mismatch repair protein in A431 cells (Fig. 11); loss of mismatch repair 
protein (MSH2) can be detected in CP500N cells. Our results in general agreed with 
those obtained from other study using a different cisplatin resistant subline of A431 cells. 
The precise role of this alteration remains to be defined (Lanzi et al., 1998). 
One of the factors that demonstrated a correlation with cisplatin resistance in CP500N 
cells, was the drug induced G2M block. Cisplatin was found to induce a similar level of 
G2M block in both A431/P and CP500N cells (Fig. 9). Lanzi and co-workers 
demonstrated that cisplatin induced a similr level of G2M block in both the cisplatin 
sensitive and resistant cells (Lanzi et al., 1998). Both Lanzi，s and our results showed 
that cell cycle perturbation cannot explain why CP500N cells were more resistant than 
the parent cells to cisplatin. 
Cytotoxicity and the resistance mechanisms of certain anti-cancer drugs might be related 
to the apoptosis, mitochondrial membrane potential and the reactive oxygen species 
formation (Burger et al., 1998，Raaphorst et al., 1998 and Eliopoulous et al., 1995). 
Table 4 summarized the results of drug sensitivity assay, apoptosis, JC-1, HE and DCF 
staining (Fig. 5, 12, 13 and 14). For the treatment of cisplatin and taxol, the parent cells 
showed a higher extent of drug sensitivity, drug induced apoptosis, mitochondrial 
depolarization and superoxide formation. The results suggested that the resistance to 
cisplatin and taxol in CP500N cells have a correlationship between the reduced level of 
DNA fragmentation, mitochondrial depolarization and the superoxide formation. For 
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doxorubicin, other than superoxide formation, correlation was observed between drug 
sensitivity, apoptosis and mitochondrial depolarization of which the parent cells is higher 
than the CP500N cells. For 5-fluorouracil and vincristine, it was surprised to see that 
A431/P and CP500N cells had difference in drug induced apoptosis, mitochondrial 
depolarization and superoxide formation while their drug sensitivity was similar. 
Nevertheless, a further study is necessary in order to confirm the correlation observed for 
different drugs. 
Table 4. Summarized results of drug sensitivity assay, apoptosis, JC-1, HE 
and DCF staining. 
Cisplatin Taxol Doxorubicin 5-Fluorouracil Vincristine 
MTT sensitivity P ^ P ^ P ^ No difference No difference 
Apoptosis P>N P>N P>N P>N P ^ 
JC-1 (Mitochondrial) P ^ P ^ P ^ P ^ 
HE (Superoxide) P ^ P ^ P ^ P ^ P ^ 
DCF (H2O2) No difference No difference No difference No difference No difference 
P: A431/P cells. 
N: A431/CP500N cells. 
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CHAPTER TWO 
THE INTERACTION BETWEEN DRUG RESISTANCE AND GROWTH 
FACTOR SIGNALLING PATHWAY 
2.1 INTRODUCTION 
Growth factors, a diverse group of polypeptides that modify cell proliferation, constitute 
a distinct subgroup in endocrinology. Many growth factors probably operate in a 
paracrine fashion and，in certain instances, their action may be autocrine in nature 
(Carpenter and Cohen, 1990). Epidermal growth factor (EGF), one of the most 
commonly studied growth factor, was first separated from nerve growth promoting 
substance by Stanley Cohen in 1960. Human homolog of EGF was discovered and 
found to be important for the biological effects in cellular response and regulation of 
ongoing physiological process (Elder, 1994 and Burgess, 1989). 
EGF is synthesized as a precursor of 1217 amino acids which includes at least seven 
repeat amino acid sequences homologous to the original 53 amino acid EGF mitogen, 
devoid of alanine, phenylalanine, and lysine (Burgess, 1989 and Carpenter, 1979). EGF 
binds to its receptor, epidermal growth factor receptor (EGFR). EGFR was the first 
member described from a family of protein tyrosine kinase transmembrane growth factor 
receptors (Bookman, 1998). After the binding of EGF to specific cell surface EGFR, a 
number of early cellular responses culminating in DNA replication and cell proliferation 
was induced (Chen and Lin, 1993). 
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The human EGFR is a transmembrane cell surface growth factor receptor. The 
occurrence of EGFR has been studied in human malignancies and its status had been 
proposed to be a prognostic indicator for the occurrence of tumors (Davies and 
Chamberlin，1996). Most of the human tumors identified to be associated with EGF-
related abnormality are found to have increased expression of EGFR. A significant 
fraction of head and neck cancer and lung epidermoid carcinomas exhibited increased 
EGFR protein (Bromberg et al., 1998; Davies and Chamberlin, 1996 and Chen and Lin, 
1993). Therefore, the presence of EGFR is indicative of a poor prognosis for the 
patient. 
2.1.1 Structure of EGF and EGFR 
EGF is a single polypeptide chain of 52 amino acid residues, devoided of alanine, 
phenylalanine, and lysine. The primary amino acid sequence of mouse EGF (mEGF) 
and the location of the three intramolecular disulfide bonds are shown in Figure 16. 
Among the 53 amino acid residues comprising the human and mouse EGF polypeptides, 
37 are common to both molecules, and the 3 disulfide bonds are formed in the same 
relative positions (Carpenter, 1979 and Elder, 1994). Although human EGF has not 
been as well characterized as the mouse-derived polypeptide, the available data indicate 
that the two polypeptides are very similar but not identical with respect to their chemical 
and physical properties (Carpenter, 1979). 
The mature EGFR is a 170 kDa transmembrane glycoprotein that is over-expressed in 
human malignancies including cancers of the lung, head and neck, brain, bladder, and 
64 
breast (Gulli et al., 1996). It is composed of a single polypeptide chain of 1186 amino 
acid residues and a substantial amount (approximately 40,000 Da) of N-linked 
oligosaccharide. A single hydrophobic membrane anchor sequence separates an 
extracellular ligand-binding domain from a cytoplasmic domain that encodes an EGF-
regulated tyrosine kinase (Carpenter and Cohen, 1990). 
The proposed structure-function topology of the EGFR is shown in Figure 17. This is a 
four-domain model for the organization of the extracellular portion of the EGF receptor. 
In this model, domains II and IV represent the cysteine-rich regions of the extracellular 
domain. Domain III and domain I are proposed to enable the receptor to interact 
specifically with EGF or transforming growth factor a (TGFa). These two domains are 
formed by the cysteine-rich regions which would be in contact with each other and close 
to the plasma membrane. Most of the structural determinants suggested that domain I 
and III were proposed to define the EGF binding affinity in the cleft formed between 
them (Ullrich and Schlessinger, 1990). 
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Figure 16. The primary amino acid sequence of mEGF. 
Structure of EGFR 
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Figure 17. The proposed structure-function topology of EGF. 
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1 
2.1.2 Growth Factor Signal Transduction Pathway 
The growth factor binds to the receptor and induces autophosphorylation by the receptor 
tyrosine kinase (RTY) (Fig. 18). It then stimulates the phospholipase C and generates 
the metabolite IP3 which acts as a second messenger molecule to liberate stored Ca^ "" from 
the endoplasmic reticulum, and thereby activates calcium-requiring enzymes or processes. 
Another metabolite is the DAG which is an activator of protein kinase C and controls the 
intracellular uptake of Ca""" ions (Carpenter and Cohen, 1990). 
The second cascade is through the activation of JAK-STAT pathway of which the 
proteins translocate to the nucleus and activate specific gene transcription. The third 
cascade is thru the Ras/Raf pathway of which the adaptor protein Grb2 will bind to the 
activated receptor. The binding would subsequently lead to activation of Raf/MEKK, 
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Figure 18. The growth factor signal transduction pathways 
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2.1.3 Biological Effect of EGF 
Early studies with EGF in intact animal demonstrated its stimulatory effect on epidermal 
proliferation and inhibitory effect on gastric acid secretion (Carpenter and Cohen, 1990). 
Initial observations have centred around the proliferative effects of these molecules on 
fibroblasts, keratinocytes and epithelial cells. However, the proliferation of some 
squamous cell carcinomas (with elevated EGF receptor levels) and the production of 
wool fibres from hair follicles are inhibited by EGF (Burgess, 1989). Other biological 
effects of EGF include activation of glycolysis, activation of the synthesis of extracellular 
macromolecules, activation of RNA and protein synthesis, initiation of DNA synthesis， 
and increase in cell multiplication (Chen and Lin, 1993). 
EGF is known to control the growth and differentiation in a number of cell types. 
Enhanced or altered activity of one or more components of the EGF-signal-transduction 
pathway may play a role in tumorigensis in epithelial tissues (Konger and Chan, 1993). 
The growth effect of EGF was particularly striking for the breast carcinomas [13 tumors 
(93%) with 100% growth increase] but less impressive for genitourinary carcinomas 
(Singletary et al., 1987). 
Some reports show that EGF stimulates the growth of many normal and malignant cell 
lines. Nevertheless, a number of tumor cell lines that contain high numbers of EGFR 
are growth inhibited by EGF (Bookman, 1998; Bromberg et al, 1998; Barnes et al., 1982; 
Konger and Chan, 1993 and Gulli et al., 1996). Bookman has reported that normal 
ovarian epithelium is growth-stimulated by exogenous EGF while ovarian carcinoma cell 
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lines are usually growth-inhibited (Bookman, 1998). 
The response of cells to the growth factor might also be concentration dependent. Some 
reports show that low concentration (pmolar) of EGF can stimulate the tumor cells while 
high concentration (nanomolar) would have inhibitory effect. EGF stimulates the 
growth of several types of cell in culture, and the proliferative effect has been proposed to 
be due to activation of receptor tyrosine kinase (Gulli et al., 1996). Treatment of A431 
cells with 10 nM EGF induced a 5-fold increase in EGFR autophosphorylation, leading to 
the inhibition of cell proliferation and morphological features of apoptosis. By the way, 
at a lower concentration of EGF (0.01 nM), there is a 2-fold increase in EGFR 
autophosphorylation and increased cell proliferation when compared to untreated cells 
(Gulli et al, 1996). 
Another experiment has examined the effects of inhibitory and stimulatory concentrations 
of EGF on the growth and differentiation of A431 cells. In the presence of 100 pM EGF, 
A431 cells showed a mild increase in growth rate (129% of control) compared to cells 
grown in the absence of EGF. At higher concentration (10 nM EGF), there is a growth 
inhibition to 63% of the control cells. EGF at 10 nM stimulates a 2-fold increase both in 
cornfield envelope formation and in epidermal transglutaminase activity, suggesting that 
high concentrations of EGF induce terminal differentiation in A431 cells. Mitogenic 
concentrations of EGF (100 pM) had no significant effect on these differentiation 
markers (Konger and Chan, 1993). Therefore, the response of cells to EGF was being 
of an interest to study in different cell systems. 
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2.1.3.1 Modification of Drug Sensitivity by EGF 
In addition contribution to the cellular activity, EGF was also found to modulate the 
sensitivity of certain cells to anticancer drugs, such as cisplatin and doxorubicin. 
EGF treatment has been shown to protect breast cancer MDA-231 cells from death 
induced by antinomycin D and doxorubicin (Geier et al., 1994), and to enhance the 
expression of the EGFR in the drug resistant cell lines. This suggests a role for EGFR 
signalling in Pgp-mediated drug resistance (Davis and Chamberlin, 1996). The results 
from these reports suggested that EGF, apart from their mitogenic effect, could function 
as survival factors for cells in growth factor-deprived medium or for cells subjected to 
cytotoxic drugs (Geier et al.’ 1994). 
The anti-cancer drugs may exert their cytotoxic effect through an inhibition / interference 
in the normal protein synthesis process, although their primary effect induces damage in 
the DNA or RNA arrangement. Growth factors may protect those injured cells by the 
mechanism as mentioned above, i.e. maintaining the critical level of some vital protein 
molecules through a posttranslational modification effect (Geier et al., 1994). 
Alteration of signal transduction pathways in the EGF/HER-2/neu receptor family of 
receptors can influence the sensitivity of a number of cell lines to cisplatin and other 
chemotherapeutic agents in culture (Mendelsohn and Fan, 1997). EGF enhances the in 
vitro sensitivity of cell lines derived from many types of malignancies, including colon 
carcinoma, cisplatin, 5-fluorouracil, taxol and melphalan. The experiment from 
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Kronging showed that EGF could enhance selectively the in vivo toxicity of cisplatin in 
human ovarian carcinoma 2008 cells xenografts without altering the toxicity of cisplatin 
to malignant target tissues such as the kidney or bone marrow (Kroning et al., 1995). 
A number of studies have explored the use of anti-EGFR antibodies to inhibit the growth 
of cancer cells in vitro and in vivo. Anti-EGFR antibodies that block ligand binding also 
inhibit in vitro growth of cells that over-express EGFR (Davies and Chamberlin, 1996). 
Recent study suggested that combination of AS S-oligos directed against EGF-related 
growth factors and of conventional anti-tumor drugs may result in efficient inhibition of 
colon-carcinoma cell growth (Luca et al； 1997). It might cause reduced activation of 
signal transduction pathway that appears important in determining the sensitivity of 
cancer cells to various anti-tumor drugs. AS S-oligo pre-treatment was also found to 
reduce the sensitivity of GEO cells to the alkylating agent cisplatin, a non-phase-specific 
agent that is assumed to be able to kill cells in every phase of the cell cycle (Luca et al., 
1997). It has been reviewed that reduced expression of EGFR achieved by introduction 
of the EGFR antisense oligonulceotides is associated with increased resistance to 
cisplatin in MDA-468 human breast cancer cells, which express high levels of EGFR 
(Mendelsohn and Fan, 1997). An anti-EGF-receptor-blocking antibody substantially 
enhances the effects of doxorubicin and cisplatin against A431 human epidermoid-
carcinoma cells and MDA-MB-468 human breast-carcinoma cells, suggesting that the 
blockade of an autocrine loop operating through this receptor might increase the efficacy 
of chemotherapeutic drugs (Luca et al., 1997). Expression levels of the EGF receptor, 
whose downregulation has been reported to be associated with the cisplatin-resistant 
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phenotype of selected models, were slightly, but not significantly reduced in A431 
cisplatin resistant cells (Lanzi et al., 1998). 
Ligand-induced activation of the EGFR tyrosine kinase and the subsequent intracellular 
signal-transduction pathway might alter one or more components of the cellular-damage 
response that is involved in regulating sensitivity of human cancer cells to cytotoxic 
drugs (Luca et aL, 1997). Other than the growth factor induces the signal transduction, 
some other DNA damaging agents, like drugs and stress protein will also affect the 
signalling pathway. It might affect the Ras/Raf signalling pathway and induces the 
MAPKKK, MAPKK, and MAPK and induce the signal transduction (Begum and Ragolia， 
1999; Gulli et aL, 1996 and Farmland et aL, 1991). 
Therefore, the drug resistance mechanisms might somehow interact with the signalling 
pathway (Davies and Chamberlin, 1996; Mendelsohn, 1997 and Luca et al., 1997). By 
modifying the signalling pathway in cells, the sensitivity to anti-cancer drugs might also 
be altered. These interactions seem to be a new approach to treat human cancer today. 
Instead of using high doses of anti-cancer drugs, it is possible to enhance the anti-tumor 
activity by perturbation of signal transduction pathway. 
73 
2.2 OBJECTIVES 
Modification of signalling pathway is a new approach to enhance the anti-tumor activity 
instead of using high doses of anti-cancer drugs (Mendelsohn and Fan, 1997). To 
examine how growth factor signalling pathway interacts with drug sensitivity 
mechanisms, human squamous carcinoma A431 cells were conditioned in the epidermal 
growth factor (EGF) and the drug sensitivity pattern of these cells were further studied. 
Since agents targeting growth factor signalling is currently used in cancer therapy and 
they are in general administrated together with other anti-cancer drugs such as cisplatin. 
It will be of interest to understand how these agents may have any effect on the drug 
resistance development in cancer cells. The A431 subline was derived by concomitant 
treatment of the cells with cisplatin and EGF. Unlike other anit-cancer drugs, EGF used 
in the conditioning process as the growth factor will only act on EGF signalling pathway. 
The differences in the response to growth factor, inhibitors, anti-cancer drugs and 
mechanisms were studied and compared in A431 parent cells with two of its sublines; 
cells conditioned with EGF only and cells conditioned with cisplatin and EGF. 
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2.3 MATERIALS AND METHODS 
2.3.1 Materials 
Chemicals Company 
� a F G F Peprotect 
� A n i s o m y c i n Calbiochem 
� A n t i - E G F R Santa Cruz 
� A n t i - P Y 9 9 Santa Cruz 
� A p i g e n i n Calbiochem 
� b F G F Peprotect 
�Calphost in C Calbiochem 
� C a l y c u l i n A Calbiochem 
� C i t r i c acid USB 
~ EcoRI New England Biolab 
~ EGF Peprotect 
~ Formaldehyde Sigma 
� H 8 9 . H C 1 Biomol 
�Herbimycin A Calbiochem 
�Hindlll New England Biolab 
� N y l o n membrane Amersham 
� O k a d i c acid Calbiochem 
� P D 9 8 0 5 9 Calbiochem 
� P D G F - b b Peprotect 
� R a p i d - h y b uffer Amersham 
�Redipr ime DNA labeling system Amersham 
~ Suramin Calbiochem 
� T y r o p h o s t i n A25 Calbiochem 
� T y r o p h o s t i n B42 Calbiochem 
Instruments Company 
~ Hybridization incubator Robbins Scientific 
�Sequi-Gen(R) GT Sequencing Cell BIORAD 
� U V cross-linker UVP 
The others materials were shown in the section of materials and methods of Chapter One 
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2.3.2 METHODS 
2.3.2.1 Cell Lines 
Human squamous carcinoma A431 cells, and its sublines were cultured in Dulbecco 
modified Eagle's medium (DMEM) (Life Technologies, Inc., USA) supplemented with 
10% fetal bovine serum (Life Technologies, Inc.，USA) and 5 mM L-glutamine (Life 
Technologies, Inc., USA) in 37°C humidified 10% CO2 incubator. 
Epidermal Growth Factor (EGF) Conditioned Cells Lines (A431/50x30) 
A431/P cells in a 75 cm^ culture flask were cultured with 50 ng/ml EGF continuously for 
30 weeks. These conditioned cells were named as A431/50x30 cells. 
Cisplatin and EGF Conditioned Cell Lines (A431/CP500E) 
80% confluent A431/P cells in a 75 cm^ culture flask were treated with 100 (ig/ml 
cisplatin together with 50 ng/ml EGF for 1 h. After treatment, the cells were grown in 
fresh medium containing 50 ng/ml EGF continuously. The cells selected from this 
condition were named as A431/CP100E cells. A431/CP250E cells were obtained by 
treating A431/CP100E cells with 250 [xgjml and 50 ng/ml EGF for 1 h and then culturing 
in 50 ng/ml EGF until confluency. Finally, A431/CP250E cells were treated with 500 
M-g/ml cisplatin for 1 hour in the presence of 50 ng/ml EGF incubation, the cells survived 
thru continuous 50 ng/ml EGF were named as A431/CP500E cells. These CP500E cells 
would be used in the following experiments. 
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2.3.2.2 Drug Sensitivity Assay 
The effect of chemotherapeutic agents on the growth of the cells was determined by MTT 
assay. A431/P (6xl0'), CP500N (2xl0'), CP500E (7xl0') and 50x30 (1.2x10^) cells 
were seeded in 96-well flat bottom plates for 2 days to reach the exponential phase. The 
details were reported in section 1.3.2.1. 
2.3.2.3 Northern Blot Analysis 
RNA was prepared as described Section 1.3.2.10. 10 i^g RNA was resolved in 1% 
agarose/7M formaldehyde denaturing gel, and transferred onto a nylon membrane. The 
RNA on the nylon membrane was fixed with an UV cross-linker. The nylon membrane 
was equilibrated in 2X SSC and prehybridized in 10 ml Rapid-hyb buffer at 65°C for 30 
minutes in a hybridization oven. The specific cDNA from PCR was denatured at 100°C 
for 5 minutes, kept on ice and labeled with Rediprime DNA labeling system with 5 fil 
:32p]-dCTP. The cDNA probe was kept in 37°C for 10 minutes and the reaction was 
stopped by adding 5 \x[ 0.2 M EDTA. The radiolabeled cDNA probe was denatured at 
100°C for 5 minutes, kept on ice for 5 minutes and mixed with the Rapid-hyb buffer. 
The membrane after prehybridization was labeled with this radiolabeled cDNA probe in a 
65°C hybridization oven for 2 hours. The membrane was washed with Solution A for 
20 minutes once, Solution B for 15 minutes twice and 2X SSC for 5 minutes at 65°C. 
After stringent washes, membranes were exposed to X-rays film with intersifying screen 
at -80�C. 
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2.3.2.4 Southern Blot Analysis 
DNA was prepared as in Section 1.3.2.7. 10 \ig genomic DNA was digested with EcoRI 
and Hindlll restriction enzyme at 3 7 � C . The digested DNA was resolved in a 1% 
agarose gel, transferred to a nylon membrane and fixed onto the membrane with a cross-
linker. Cytoplasmic and extracellular EGFR were used as a probe for the Southern blot 
analysis. The method was the same as the Northern blot analysis (Section 2.2.2.3). 
2.3.2.5 Others 
The procedures for Western blot analysis; DNA fragmentation; JC-1, HE and DCF 
staining; Glutathione determination and Quantitative RT-PCR were described in the 
sections of Materials and Methods in Chapter One. 
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2.4 RESULTS 
2.4.1 Sensitivity to EGF 
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2.4.2 EGFR Expression Levels 
EGF exerts its biological effect, such as growth effect, thru receptor autophosphorylation 
and subsequent phosphorylation of other proteins. Hence, Western blot analysis using 
antibody to phosphotyrosine was used to examine the protein phosphorylation profile in 
different A431 cells. The basal level of EGFR in A431 cells was shown in Figure 20a. 
The total EGFR levels in all the four cell lines were nearly the same, except the level of 
EGFR in CP500E cells was slightly higher (Fig. 20b). 
However, the levels of activated EGFR among the A431 sublines were totally different 
from the A431/P cells (Fig. 20c). EGFR has a molecular size of 170 kDa. The 
activated EGFR protein levels are the highest in CP500N cells. However, the 
conditioned cells (CP500E and 50X30 cells) have a lower expression of activated EGFR 
levels. The EGF conditioned treatment suppressed the basal activity of EGFR in cells. 
When comparing the result of CP500E cells with CP500N and 50X30 cells，the data 
showed that the EGF conditioned treatment overcome the cisplatin treatment effect on 
EGFR activation in cells. 
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Figure 20. The protein phosphorylation profile in different A431 cells by Western 
blot analysis. 
(a) The basal level o fEGFR in A431 cells (probe with anti-EGFR antibody). 
(b) The intensity of basal EGFR expression as quantified by densitometer. 




The basal level of EGFR mRNA expression was detected by Northern blot analysis (Fig. 
21). The cDNA probe of cytoplamsic EGFR was used. Among the four cell lines, 
A431/CP500N cells showed the highest mRNA expression while A431/CP500E cells 
showed the least. The EGFR mRNA levels were similar for A431/P and A431/50X30 
cells. 
Results from the figure suggested that cisplatin conditioned treatment alone could induce 
the over-expression of EGFR mRNA levels (A431/P Vs A431/CP500N) while EGF 
conditioned treatment alone did not alter the EGFR mRNA level significantly (A431/P 
Vs A431/50X30 cells). The combination of both conditioning conditions however 
reduced EGFR mRNA level in cells (A431/CP500E Vs A431/P; CP500N and 50X30 
cells). 
In Southern blot analysis, the genomic DNA was digested with X-Hindlll and EcoRI 
restriction enzyme and cytoplasmic EGFR was used as the cDNA probe (Fig. 22). The 
gene copy numbers of all the four cell lines were not the same as the intensity levels were 
different. It was highest in CP500N cells, followed by the parent, CP500E and 50X30 
cells when digested with HindllL The intensity pattern in EcoRI digestion was similar 
to that shown by Northern blot analysis but not by those from Western blot analysis. 
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Figure 21. Northern blot analysis of EGFR. 
(a) The RNA was probed with cytoplasmic EGFR DNA (�2000bp). The 
cDNA probe was prepared by using the following primers 
Forward: 5 ' -AGAAGGTGAGAAAGTTAAAATTCCCGT-3' 
Reverse: 5，-ATGTAGACATCGATGGTACATATGGGT-3 ’ 
(b) 18S and 28S rRNA was shown to indicate the equal loading of the 
samples. 
{di)HindIII (h) EcoRI 
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Figure 22. Southern blot analysis of EGFR gene expression in A431 cells 
probed with cytoplasmic EGFR cDNA. 
(a) Genomic DNA digested vAth Hindlll. 
(b) Genomic DNA digested with EcoRI. 
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2.4.3 EGF Induced Protein Phosphorylation Pattern 
In EGF signalling pathway, the growth factor binds to EGFR, induces receptor 
autophosphorylation and also activates the phosphorylation of various proteins. The 
EGF induced protein tyrosine phosphorylation pattern for all the four cell lines were 
shown in Figure 23. 
For A431/P, CP500N and CP500E cells, the phosphorylation detected as early as 1 min 
after EGF was added. The degree of phosphorylation started to level off after 9 hours of 
incubation with 50 ng/ml EGF (Fig. 23a, b and c). In A431/50X30 cells, the 
phosphorylation pattern was also detected after 1 minute while the maximal was at 6 
hours and started to level off after 9 hours of incubation (Fig. 23d). The results 
suggested that the EGFR in all four sublines were functional as they are able to be 
activated by EGF. 
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Figure 23. The EGF induced protein phosphorylation pattern in A431 cells by 
Western blot analysis. The cells were incubated with 50 ng/ml EGF for up to 
48h. 15 |Lig protein were used in each lane and the antibody used was PY-20 
antibody. 
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2.4.4 Effect of EGF on A431 cells 
As shown in Figure 19，EGF has an inhibitory effect on the growth of A431/P and 
CP500N cells but has stimulatory effect on A431/CP500E and 50X30 cells. It will be of 
interest to see the effect of EGF on apoptosis in different A431 cells and how it will 
correlate with the results from the growth study. 
For A431/CP500E and 50X30 cells, 50 ng/ml and 200 ng/ml of EGF appeared to have no 
significant influence on the apoptosis in these 2 cell lines (Fig. 24); no DNA ladder could 
be detected in both cells with or without the presence of EGF. 
In contrast, DNA laddering formation could be detected in A431/P and CP500N cells 
upon treatment with EGF. 50 ng/ml EGF induced DNA ladder formation in both cells 
with a greater extent in A431/CP500N cells. At 200 ng/ml EGF, no DNA ladder 
formation was detected in A431/P celis but in A431/CP500N cells. The extent of EGF 
induced DNA fragmentation in CP500N cells was similar for cells under either 50 ng/ml 
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Figure 24. Induction of DNA fragmentation in A431 cells by EGF. 
M: lOObp marker 
C: Control 
1: 50 ng/ml EGF 
2: 200 ng/ml EGF 
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As shown by the fluorescent profile of cells with JC-1 staining, mitochondrial 
depolarization was detected in CP500E and 50X30 cells after the treatment of 50 ng/ml 
EGF but not in the parent and CP500N cells. For the HE staining, there were no 
significant differences in the superoxide formation in all the four cell lines (Fig. 25-26). 
However, the formation of hydrogen peroxide was higher in A431/P cells as detected by 
staining with DCF (Fig. 26). However, the results suggested that all of these factors, i.e. 
mitochondrial potential, superoxide and peroxide levels, do not correlate with EGF 
associated growth effect and apoptosis. 
The cell cycle distribution of A431 cells under the treatment of EGF was shown in Figure 
27. EGF induces cell cycle arrest in all the four sublines. However, the arrestment is 
more significant in CP500N cells. It might be the reason for why CP500N cells were 
more sensitive to the EGF treatment. 
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Figure 25. The mitochondrial membrane potential in A431 cells as stained by 
JC-1 dye. 
LHS: Percentage of cells in left hand side. 
RHS: Percentage of cells in right hand side. 
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• : Cells treated with EGF. 
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Figure 27. Cell cycle distribution of cells with the treatment of 
EGF. The cells were stained by propidium iodide. 
• : Untreated cells 
• : Cells treated with 50 ng/ml EGF at the corresponding time. 
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2.4.5 Response of Cells to Agents Targeting EGF Signalling Pathway 
Since the EGF conditioned cells have difference in EGF related growth response and 
related phosphorylation pattern as compared to the parent cells, one could further 
characterized the cell lines by examining their responses to different agents that targeting 
different parts of the signalling pathways, e.g. phosphatases and kinases inhibitors. 
Such information may be useful for a further understanding of the effect of EGF 
conditioning on growth factor signalling pathway. 
The results of the response of A431 cells to the modifiers were shown in Figure 28. The 
active mechanisms of various modifiers were summarized in Table 5. Different 
modifiers have different inhibitory effect on different cell lines and the results were also 
summarized in Table 5. Though not all the modifiers generated the same conclusive 
result, in general, A431/P cells were the most sensitive while CP500N cells were the 
most resistant cell line. For the response to okadic acid which targets primarily at 
phosphatase, both EGF conditioned cells appeared to be more resistant than the other 
unconditioned cells, A431/P and CP500N cells. Okadic acid was a potent inhibitor of 
protein phosphatase 1 (PPl) and protein phosphatase 2A (PP2A). The results therefore 
indicated that the phosphatase levels in cells might be altered upon EGF conditioned 
treatment. 
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Figure 28. The response of A431 cells to different modifiers as measured by 
MTT assay. 
O : A431/P cells. 
V:A431/CP500N cells. 
令：A431/CP500E cells. 
A : A431/50X30 cells. 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The mRNA expression levels of PPl and PP2A were therefore further investigated by 
quantitative RT-PCR. Figure 29(a) and (b) showed the mRNA level expression of PPl-
catalytic and PP2A-regulatory subunits. The molecular size of amplified PPl-catalytic 
and PP2A-regulatory subunit cDNA fragment is 516 bp and 530 bp, respectively. The 
levels of these two subunits in A431/P and CP500E cells were higher than that in the 
A431/CP500N and 50X30 cells. 
For the expression of PP2A-catalytic site with |3 subunit, the results were shown in Figure 
29. The molecular size for the amplified fragment is 665 bp. PP2A-catalytic site was 
over-expressed in A431/P cells but not in other cells. Results from the RT-PCR study 
did not conclude that the response of cells to okadic acid would correlate with the mRNA 
expression of the phosphatase. However, the role of the enzyme activity in okadic acid 
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Primer Sequence Size Results 
权HCjait，^^伴 (F) 5'-TACTACGACCTTCTGCGACTATTTG-3' 516 bp E>P>N�X 
面 
PP2A-regulatoiy (f ) 5'-GTCATGCCGATCTGTCTCGATAC-3' 530 bp E>P�N>X 
(R) 5'-TCTCATACTCCTCAGCTGCAAAC-3' 
m A ^ R ^ l y i i c 665 bp P > N各X 
(R) 
G3DH (F) 5'-ACCACAGTCCATGCCATCAC-3' 451 bp P~N~B^X 
ICR) 5'-TCCACCACCCTGTTGCTGTA-3' 
Figure 29. The phosphatase m R N A expression levels in A431 cells by quantitative 
R T - P C R . Glyceroaldehyde-3 -dehydrogenase ( G 3 D H ) w a s used as an internal 
standard to indicate the equal amount of sample. 
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2.4.6 Response of Cells to Other Growth Factors 
Signalling pathway of an individual cytokines may cross-talk to other pathways and 
therefore modification of any one of these pathways may also alter the activity of the 
other pathways. As the EGF signalling pathway in A431/CP500E and 50X30 cells were 
found to be altered after conditioning in EGF (Fig. 19), with respect to growth factors 
cross-talk, the response of these cells to other growth factors was also examined by MTT 
assay (Fig. 31). The growth factors were acidic-FGF, basic-FGF, TNF-a, PDGF-bb and 
TGF-(3. 
For the response to a-FGF and b-FGF, there is a growth stimulatory effect in all the four 
cells. The extent of stimulation is the least in A431/CP500E cells (Fig. 30). Such 
pattern was different from the response of cells to EGF of which a suppression effect was 
observed for those non-EGF conditioned cells (A431/P and CP500N cells) (Fig. 19). 
For the response to TGF-|3, the cisplatin conditioned cells (A431/CP500N and CP500E 
cells) were more resistant than the non-cisplatin conditioned cells (A431/P and 50X30 
cells). The sensitivity to TNF-a were in the following orders (CP500E > 50X30 > P > 
CP500N). EGF conditioned cells were more resistant to TNF-a than those non-
conditioned cells. For the response of PDGF-bb, there is no clear-cut difference among 
different cells. The results from the study indicated that either cisplatin or EGF 
conditioning will likely alter the response of cells to other growth factors. 
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Figure 30. The response of A431 cells to different growth factors as measured by 
MTT assay. 
O : A431/P cells. 
V : A431/CP500N cells. 
O : A431/CP500E cells. 
A: A431/50X30 cells. 
error bar: standard deviation from more than three different experiments. 
Table 6. The response of A431 cells to different growth factors. 
Growth factors Results 
(a) acidic-FGF N � � P � E � X 
(b) basic-FGF X � N > P � � E 
(c) TGF-B No difference 一 
(d) PDGF-bb No difference — 
(e) TNF-g E>X>P>N 一 
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2.4.7 Sensitivity of Cells to Different Anti-cancer Drugs 
Results from Figure 19 indicated that the EGF conditioned cells and CP500N cells had 
different in their response to EGF and other growth factors. In the following 
experiments, the sensitivity of these cells to anti-cancer drugs was examined to see how 
drug sensitivity pattern of these cells might be altered after EGF conditioning treatment 
(Fig. 31). Several anti-cancer drugs (cisplatin, camptothecin, doxorubicin, etoposide, 5-
flurouracil, vincristine, methotrexate and taxol) and y-irradiation were used. 
As mentioned in Chapter one, in addition to cisplatin resistance, A431/CP500N cells 
were also cross-resistance to several other anti-cancer drugs. For the response to 
cisplatin, doxorubicin, taxol, camptothecin and genistein, CP500N cells were the most 
resistant one while A431/P cells were the most sensitive (Fig. 31). The prolonged EGF 
conditioning treatment might affect the sensitivity of cells to several anti-cancer drugs. 
EGF conditioned cells (50X30 and CP500E cells) were more resistant to doxorubicin, 
taxol, genistein, 5-fluorouracil, vincristine, etoposide, methotrexate and y-irradiation than 
the unconditioned cells，A431/P cells. For example, in the case of 5-fluorouracil, the 
cytotoxic effects of 5-fluorouracil for A431/P and CP500N cells were higher than that in 
A431/CP500E and 50X30 cells. The I Q � o f A431/CP500E and 50X30 cells were 0.2 
fxg/ml and 0.1 ！ig/ml respectively. 
The EGF conditioning treatment can also overcome the cisplatin-induced cross-resistance 
to the drugs as CP500E cells are no longer more resistant to those anti-cancer drugs as 
CP500N cells did. These anti-cancer drugs include cisplatin, taxol, camptothecin and 
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genistein. For example, the cisplatin resistance as shown in CP500N cells was 
overcome by the concomitant treatment of cells with EGF at the time of developing the 
cell lines (CP500E cells). The response of A431/CP500E cells to cisplatin is 2 times 
more sensitive than CP500N cells, while there is no significant difference when compare 
the sensitivity of cells with that of the parent and 50X30 cells. 
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Figure 31. The response of A431 cells to different anti-cancer drugs as measured by 
MTT assay. 
O : A431/P cells. 
V:A431/CP500N cells. 
令：A431/CP500E cells. 
A : A431/50X30 cells. 
error bar: standard deviation from more than three different experiments. 
Table 7. SiirriTrianzed of drug sensitivity assay in A431 c e l k 
Anti-cancer drugs Results Anti-cancer drugs Results 
Cisplatin N > X � E � P 5-Fluorouracil E>X>P � N 
Doxorubicin N>E>X~P Vincristine E � X > N � P 
Taxol N>X>E>P Etoposide E>N>X>P 
Camptothecin N>X>E�P Methotrexate E � N � X > P 
Genistein N>X>E>P y-irradiation E>X>P � N 
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2.4.8 Drug Resistance Mechanisms (Drug Detoxification Agent) 
GST，GSH, P-glycoprotein and MRP are well-known drug resistance factors in cells. 
As different conditioned A431 cells demonstrated differences in response to different 
anti-cancer drugs, the resistance mechanisms were examined. 
Etharyanic acid is a GST inhibitor. A431/50X30 cells have a higher percentage of cell 
survival while the other three sublines showed a lower percentage upon the treatment 
with etharyanic acid (Fig. 32). A431/50X30 cells were the most resistant one among all 
the four cell lines, while the sensitivities were the same in A431/P and CP500E cells. 
By Western blot analysis, the GST protein level was the least in 50X30 cells in which 
might also not correlate with the data from MTT assay. The GST protein levels in 
A431/CP500E cells were the highest but this cannot explain why CP500E cells were 
sensitive to etharyanic acid (Fig. 33). In addition, the glutathione content was the 
highest in CP500E cells (Fig. 34). The resistance mechanism in A431/CP500E cells 
might be related to the GST protein level and cellular glutathione content. 
103 
1 叫 ‘ 
1—‘—r—‘—I—‘—I—"—I 
0 5 10 15 20 
Concent ra t ion (fxM) 
Figure 32. The response of A431 cells to etharyanic acid as measured by MTT assay. 
O : A431/P cells. 
¥ : A431/CP500N cells. 
令:A431/CP500E cells. 
A : A431/50X30 cells. 
error bar: standard deviation from three different experiments. 
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Figure 33. Figure 34. 
The GST level in A431 cells as detected by The intracellular glutathione content in A431 
Western blot analysis. cells. 
Error bar: standard deviation from three 
different experiments. 
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P-glycoprotein is another well-known drug resistance protein. From Western blot 
analysis，the P-glycoprotein is over-expressed in A431/CP500E cells (Fig. 35a). By 
quantitative RT-RCR, P-glycoprotein can only be detected in A431/CP500E cells (Fig. 
35b). Therefore, P-glycoprotein might play an important role in the drug resistance 
pattern in A431/CP500E cells. 
The basal mRNA levels of MRP were the same among the four cell lines as assessed by 
quantitative RT-PCR (Fig. 36a). Therefore, the difference in the resistance to some anti-
cancer may not be related to the presence of MRP. In Western blot analysis, 
topoisomerase II levels were over-expressed in A431/P, CP500N and CP500E cells (Fig. 
36b). The down-regulation of topoisomerase II level in 50X30 cells has the same 
pattern in the expression of P-glycoprotein. 
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(a) P-glycoprotein (b) 
^ ’ (170 kDa) 
I 1 i I (285 bp) ^ T H i n i B 
^ b & ^ 
Primers for P-glycoprotein: 
Forward: 5'-GCCTGGCAGCTGGAAGACAAATACACAA-3' 
Reverse: 5'-CAGACAGCAGCTGACAGTCCAAGAACAGGA-3' 
Primers for G3DH: 
Forward: 5'-ACCACAGTCCATGCCATCAC-3， 
Reverse: 5'-TCCACCACCCTGTTGCTGTA-3' 
Figure 35. The P-glycoprotein levels in A431 cells as detected by Western blot 
analysis and quantitative RT-PCR. 
(a) P-glycoprotein levels by Western blot analysis. 
(b) P-glycoprotein levels by quantitative RT-PCR. 
G3DH was used as an internal standard to indicate the equal amount of sample. 
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Primers for P-glycoprotein: 
Forward: 5'-AGAACCTCAGTGTCGGGCAGCG-3' 
Reverse: 5，-TCGCATCTCTGTCTCTCCTGGG-3’ 
Primers for G3DH: 
Forward: 5'-ACCACAGTCCATGCCATCAC-3， 
Reverse: 5'-TCCACCACCCTGTTGCTGTA-3' 
Figure 36. The drug resistance related genes, MRP, and topoll，in A431 cells. 
(a) MRP mRNA levels by quantitative RT-PCR with the above primers. 
G3DH was used as an internal standard to indicate the equal amount of sample 
loaded. 
(b) Topoisomerase II protein levels as detected by Western blot analysis. 
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2.4.9 5-FluorouraciI Sensitivity in A431 Cells 
The result from Figure 19 showed that A431/CP500E and 50X30 cells (EGF conditioned 
cells) were relatively more resistant to 5-fluorouracil treatment. The resistance 
mechanisms to 5-fluorouracil were investigated in order to understand the characteristics 
of A431/CP500E and 50X30 cells. 
As shown in Figure 37, 5-fluorouracil treatment induced DNA fragmentation in A431/P, 
CP500N, 50X30 cells，but not in the A431/CP500E cells. Therefore, the resistance to 5-
fluorouracil in EGF conditioned cells (both A431/CP500E and 50X30 cells) may be 
partly due to the reduction of 5-fluorouracil induced apoptosis. 
The mitochondrial membrane potential was detected by flow cytometric analysis with 
JC-1 dye staining (Fig. 38). From the result, the 5-fluorouracil treatment induced the 
mitochondrial membrane depolarization in all of the four cells. By comparing the 
percentage of cells in the right hand side, the effects are more significant in A431/P and 
CP500E cells. 
In the investigation of 5-fluorouracil induced ROS formation, 5-fluorouracil treatment 
induced superoxide formation in A431/CP500N cells and CP500E cells; but not in the 
other two cell lines. However, the levels of hydrogen peroxide formation were not 
affected by 5-fluorouracil in all the four cell lines. 
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Figure 37. Detection of apoptosis in A431 cells by DNA fragmentation 
with the treatment of 5-fluorouracil for 48h. 
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F i g u r e 38. T h e m i t o c h o n d r i a l Figure 39. The induction of superoxide 
depolorization in A431 cells as stained by and hydrogen peroxide by the 48h 
JC-1 dye after the treatment of 5- treatment of 0.3 lug/ml 5-fluoroiiracil as 
fluorouracil for 48 h. stained by HE and DCF respectively. 
LHS: Percentage of cell in left hand side. Untreated cells. 
RHS: Percentage of cell in right hand side. 口：（ells t reated with S-fu. 
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The cell cycle distribution after the treatment with 5-fluorouracil for 48 h was shown in 
Figure 40. 5-Fluorouracil induced G2M block in A431/P and CP500E cells in a great 
extent but not in A431/CP500N and 50X30 cells. Though A431/CP500E cells were 
resistant to 5-fluorouracil, an induction of cell cycle change can be detected. Therefore 
resistance mechanisms to 5-fluorouracil might not be related to cell cycle distribution. 
Generally speaking, cellular sensitivity to 5-fluorouracil correlates with the expression of 
thymidine synthase and dihydrofolate reductase. The thymidine synthase and DHFR 
expression in different A431 cells was detected by Northern blot analysis (Fig. 41). 
Those mRNA were over-expressed in A431/P, CP500E and 50X30 cells. This might be 
one of the reasons why A431/CP500N cells were very sensitive to 5-fluorouracil. 
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Figure 40. Cell cycle distribution of cells with the treatment of 0.3 ^ig/ml 
5-fluorouracil for 48 h as stained by propidium iodide. 
• : Untreated cells 
• : Cells treated with 5-fu 
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Figure 41. The mRNA level of (a) dihydrofolate reductase and (b) 
thymidine synthase in A431 cells as detected by Northern blot analysis. 
The 18S and 28S rRNA is an indicator of the equal amount of RNA 
samples was loaded. 
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2.4.10 Cisplatin Sensitivity in A431 Cells 
Though A431/CP500E cells were established thru the selection with cisplatin, the 
response of cells to cisplatin was as sensitive as that of the A431/P and 50X30 cells (Fig. 
31). To find out how EGF conditioned treatment may modify cisplatin resistance 
development, the induction of apoptosis and perturbation of cell cycle by cisplatin in 
CP500N and CPSOOE cells were compared. 
Cisplatin induced DNA fragmentation in all the four A431 sublines (Fig. 42). The 
induction of DNA fragmentation was more apparent in A431/P and 50X30 cells than in 
CP500N and CPSOOE cells. Although there was a slightly difference in cisplatin 
induced apoptosis between CP500N and CP500E cells，the difference between them 
would unlikely be able to explain the large difference as detected by MTT assay (Fig. 
31). 
Using the JC-1 staining fluorescent profile, there was an induction of mitochondrial 
membrane depolarization in A431/P，CPSOOE and 50X30 cells by cisplatin, but not in the 
A431/CP500N cells (Fig. 43). 
Besides, the cytotoxic effect of cisplatin in all cells might not be related to the hydrogen 
peroxide formation as indicated by DCF staining profile (Fig. 44a). However, induction 
of superoxide formation, as assessed by HE staining profile, by cisplatin was significant 
in A431/P, CPSOOE but not in the 50X30 cells and CP500N cells (Fig. 44b). 
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Figure 42. Detection of apoptosis by DNA fragmentation under the 48 h 
treatment of cisplatin. 
114 
1 |Lig/ml 
C o n t r o l a s p 丨 a t i n � D C F (b) H E 
py -Height (1) vs FL3-Height (2) FJ,1 -Height (1) vs FU3-Helght (2) 
I::困 CB ii ；I i 
^ LHS: RHS: LHS: RHS: , ^.M. , ,_JBL 
^ o 82.05% 17.95% a 66.19% 33.8P/J ' ‘ 。 。 彳 二 二 化 ’ i b ' 
(1) vs FLS-MelgW (2) l^l.-Height (1) v^ FL3~Hei^ p ) 
2 1 . : “ 岂 1 . 
, I • k 
DL LHS RHS: ？- L H 發 j RHS 题 
Q n 80.3% 19.7% 83.31% 16,69°/( �— 
-Height (1) vs FL3-Heiaht (2) -Height (1) vs FL3-He^ (2) 
'-] r] n §1 5 
LLi S> s, 产:y " 
个 讓 ‘ 善 个 ^ M 
fl) 一 a . ？- LUm RHS: ？- LHSn RHS: � � r ^ 属 . . ， . Wm^ 
3 • 告 7 5 . 5 2 % 2 4 4 狄 告 45.41% 5 5 : 5 9 % xTl 
c3 r ^ ，ilo厂丄…To厂—i-io"lo® T o ' T o ' ‘ 10'' ^ ^ ^ 
bX) g Ch 
g j ^ ^ -Height (1) vs FL3+telgtt (2) f y -Height (1) vs FL3-Height (2) ^ „ 界 
<1 I ifH f H ^ il I i| • 
^ § LH^ RHS: IBM RHS: ^ Vo^  I g j ^ . Vo-
C ) 力 76.08�4 23 92% n 47 62»^  ^ aaJ^  
ym^ ^ ^ to^' lb^ ' l V 1o® "lb' V . To‘ iV 
JC-monomer Channel no. 
Channel number 
Figure 43. The mitochondrial membrane Figure 44. The (a) hydrogen 
potential in A431 cells after the treatment peroxide and (b) superoxide levels 
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The cell cycle distribution after the treatment of cisplatin was shown in Figure 45. 
Cisplatin induced the G2M block in the cell cycle distribution in all the four cell lines. 
The induced G^M block begins to release after 48-hour treatment. 
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Figure 45. Cell Cycle distribution of cells with the treatment of 1 jiig/ml 
cisplatin as stained by propidium iodide, 
B: Untreated cells. 
• : Cells treated with cisplatin. 
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2.5 DISCUSSIONS . 
The drug resistance mechanisms might interact with the growth factor signalling pathway 
in cells (Aigner et al., 2000; Cvijic et al., 1998 and Davies and Chamberlin, 1996). The 
idea was supported from the results obtained from cisplatin conditioned (CP500N) cells 
and EGF conditioned (50X30) cells. The CP500N cells demonstrated resistance to 
cisplatin and other anti-cancer drugs (Fig. 5). Other than the alteration in drug 
sensitivity pattern and the expression of drag resistant factors (P-gp and MSH2), the 
response to EGF and also to other growth factors modifiers was also found to be different 
from that of the parent cells (Fig. 19 and 28). It has been reported that EGF may induce 
different changes in A431 cells in culture, and that such effects may be associated with 
the observed growth inhibition effect (Barnes et al., 1982). As the inhibitory effect is 
higher in cisplatin resistance cells, the induced differention changes may also be higher in 
cisplatin resistant cells. The EGF conditioning process in 50X30 cells altered not only 
the signalling pathway but also the drug sensitivity pattern and drug resistance factors 
expression in cells (Fig. 28-36). Our data are consistent with the report of Konger and 
Chan (1993) and several other reports that treatment with EGF, thereby activating EGFR, 
could modify the sensitivity of cells to several chemotherapetic agents or to radiation 
therapy (Mendelsohn and Fan, 1997 and Davies and Chamberlin, 1996). The findings 
are comparable to the results from other studies as discussed in the introduction of this 
chapter and previous chapter (Davies and Chamberlin, 1996; Luca et al, 1997, 
Mendelsohn and Fan, 1997 and Faaland et al., 1991). 
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Apart from modifying the drug sensitivity pattern of cells, the process of EGF 
conditioning may also suppress the development of resistance to anticancer drug, such as 
cisplatin. Although increased cisplatin resistance of CP500N cells was confirmed by 
MTT assay, the resistance however was not detected in the CPSOOE cells (Fig. 31). A 
detailed analysis of growth factor signalling pathway will be needed to provide evidence 
for the mechanisms underlying this suppression effect. Though results from the present 
study cannot provide a conclusive evident, they do support the idea of using agents 
targeting the growth factor signalling together with other anticancer drug in cancer 
therapy. In addition to the increased drug response of the cells, the regime might also 
prevent the development of drug resistance, which is always considered as one of the 
major obstacle for cancer chemotherapy. 
Even though the growth factor might be growth inhibitory for the cells (Barnes et aL, 
1982), prolonged EGF conditioned treatment might alter the growth responsiveness of 
cells, i.e. the cells after the treatment will become growth stimulatory by the growth 
factor (Fig. 19). Such effect appeared not to be affected by the presence of cisplatin. 
EGF suppressed the growth of parent cells but stimulated the growth of CP500E and 
50X30 cells. Although the EGF associated growth effect is always thought to be the 
outcome of its signalling pathway, such relationship is still not clearly understood 
(Barnes et aL, 1982; Luca et al” 1997; Aigner et aL, 2000; Davis and Chamberlin, 1996 
and Konger and Chan, 1993). By analyzing EGFR expression at the gene，mRNA, 
protein and receptor kinase activity levels, it was found that the only difference for both 
CP500E and 50X30 from the parent cells is the basal EGFR activity. EGF 
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conditioning inactivated the basal EGFR activity as shown in C500E and 50X30 cells. 
However, the receptors in these cells are still functional, as they will be activated upon 
incubation with EGF (Fig. 23). The cellular EGFR activity is regulated by several 
factors, such as kinase, phosphatase, protein kinase C (Gulli et al., 1996; Ullrich and 
Schlessinger, 1990; Faaland et al., 1991; Davies and Chamber, 1996; Favre et al., 1997 
and Luca et aL, 1997). In the response of cells to different modifiers of signalling 
pathway, it was shown that both CP500E and 50X30 cells are more resistant to okadic 
acid than the parent cells. This suggested that the phosphatase levels in these 2 sublines 
might be different from that of the parent cells (Fig. 28). The alteration in PPl and 
PP2A levels have been reported to induce functional inhibition of STATS; JAK-2 and 
MAPK signalling (Begum and Ragolia, 1999; Woetmann et aL, 1999 and Chung and 
Brautigan, 1999). PPl and PP2A mRNA levels in cells from RT-PCR experiment 
however are not enough to make a conclusive result (Fig. 29). It may be necessary to 
measure the enzyme levels in order to clarify this hypothesis. 
Induction of apoptosis by EGF is another factor that may contribute to EGF associated 
growth response (Fig. 24). EGF induced growth suppression and also apoptosis in both 
A431 parent and CP500N cells. However, growth stimulation was observed in CP500E 
and 50X30 cells and no apoptosis was induced by EGF (Fig. 19 and 24). EGF induced 
mitochondrial depolarization is not detected in both A431 parent and CP500N cells. 
Although mitochondria are recently thought to be important in the process of apoptosis 
(Foot et aL, 1997 and Cossarizza et al., 1993), results from the present study suggested 
that they might not be an important factor in this cell system. Since some members in 
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growth factor signalling pathways were shown to affect the expression of some of the 
genes that regulate the process of apoptosis (Bookman, 1998; Konger and Chan, 1993 
and Geier et al., 1994)，it is not surprised that apoptosis will contribute partly to the 
growth factor associated growth suppression. 
In term of the influence of EGF conditioning on the drug sensitivity of cells，the 
development of drug sensitivity pattern of cells depends on the process of cisplatin at the 
time of selection (Fig. 31). In general, the EGF conditioned cells are more resistant to 
5-fluorouracil than the parent cells. Although the resistance to 5-fluorouracil is known 
to be due to the over-expression of thymidine synthase (Barnes et al., 2000 and Mader et 
aL, 2000)，the enzyme seems to be not important for the development of 5-fluorouracil 
resistance in both CP500E and 50X30 cells，as the expressions of the gene were same in 
the four cell lines (Fig. 41). However, the resistance to 5-fluorouracil in CP500E cells 
might somehow be due to the over-expression of DHFR of which over-expression is 
correlated with methotrexate and 5-fluorouracil resistance (Fig. 41) (Barnes et al, 2000 
and Mader et al.’ 2000). Furthermore, at least for CP500E cells, the 5-fluorouracil 
resistance is likely be related to the process of apoptosis as DNA fragmentation is not 
detected in CP500E cells upon treatment with 5-fluorouracil (Fig. 37). In contrast, the 
EGF conditioned CP500E cells were more sensitive to cisplatin than the CP500N cells. 
The reasons for the responsiveness to cisplatin in CP500E cells might be due to the 
mitochondrial depolarization and induction of superoxide formation (Fig. 43-44). The 
induction of apoptosis might not be an important factor for this responsiveness as no 
DNA fragmentation can be detected in CP500E cells upon the treatment of cisplatin (Fig. 
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42). Since the current belief that drug induced mitochondrial depolarization and 
superoxide formation may lead to the process of apoptosis, it is surprised to see that it is 
not the case of cisplatin treated CPSOOE cells. 
Since both signalling pathway and drug resistance mechanisms are rather complicated, it 
is difficult to make a general conclusion on how drug resistance mechanisms may interact 
with the growth factor signalling pathway. More experiments are needed on each 
specific mechanism in order to understand the detail relationship. 
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CHAPTER THREE 
IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENE IN A431 
CELLS BY DIFFERENTIAL DISPLAY 
3.1 INTRODUCTIONS 
The characteristics of different A431 sublines were presented in Chapter I and 11. The 
three sublines response differently to varous anti-cancer drugs and the EGF growth factor. 
However, the mechanisms that regulate drug resistance and growth factor signalling are 
diverse and the results obtained from the study so described in the previous two chapters 
are not conclusive. Therefore, to further examine the drug resistance mechanisms in 
details, diferential display was used to analyze the characteristics of each A431 subline. 
Furthermore, the genes that were differentially expressed were cloned and sequenced for 
detail analysis. 
Differential display was first published in 1992，and had been one of the main driving 
forces in molecular biology. It is a powerful tool to characterize and clone differentially 
expression genes among different cell lines and some of these genes might be novel. It 
is a high throughout one-tube method for systematic analysis of genes for the purpose of 
comparative study. It has been used in the area of identification and cloning of genes in 
developmental processes, pathological status particularly in cancer research, and 
enhanced understanding and discovery of pharmacological targets in cells. In the case 
of cancer therapy, determination of genetic changes associated with drug resistance may 
offer new opportunities in diagnosis and therapeutic intervention. 
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The protocol of differential display is illustrated in Figure 46. The DNA in the cell 
lysate is initially removed by the DNase I treatment. The mRNA obtained was reverse 
transcribed with oligo-dT primers anchored to the beginning of the poly(A) tail, followed 
by the PGR reaction in the presence of a second short arbitrary primer. The amplified 
short gene fragments or cDNAs were resolved and displayed by DNA sequencing gel 
electrophoresis. mRNA samples analyzed side by side allow differentially expressed 
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Figure 46. The general protocol for differential display. (Adapted from the protocol of 
RNAimage®). 
Hence, the full length cDNA clone has to be verified to understand the details in the 
relationship of drug resistance mechanisms or growth factor signalling pathway. The 
full-length of the cDNA can be obtained by the method of Rapid Amplification cDNA 
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Ends (RACE). In this chapter, after verifying the differentially expressed genes among 
the sublines, the full-length of a novel clone was amplified by Marathon cDNA 
amplification kit. The schematic diagram was shown in Figure 47. 
The size of the insert was checked by colony lysis，and reamplified by PGR using M13 
reverse (5 ‘ - G A A A C A G C T A T G A C C A T G A-3') and forward (5'-
GT1 1 1 CCCAGTCACGAC-3 ‘) primer. The size of insert was detected by running the 
PGR product on a 1% agarose gel by electrophoresis. Minipreparation and sequencing 
were performed as discussed before. The sequence obtained was aligned with the 
database from Genbank using BLAST search. 
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Figure 47. The schematic diagram of R A C E reaction. 
The Schematic drawing of 5' and 3，RACE (Rapid Amplification of cDNA Ends) for 
cloning full length novel cDNA not over-expressed in A431/CP500N cells. The 
Clontech MarathonTM cDNA amplification kit was used. First-strand cDNA was 
synthesized by reverse transcriptase of mRNA from exponentially growing A431/P cells 
with the use of modified lock-docking oligo-dT primer [cDNA synthesis (CDS) primer 
and second strand with cocktail of DNA polymerase I，RNase H and E.coli DNA ligase. 
The double stranded cDNAs were ligated with the partially double-stranded and 5'end 
phosphorylated Marathon cDNA adaptor at both ends by T4 DNA ligase. RACE (5' or 
3，end) can be performed by PGR amplification with the combination of gene specific 
primer(s) (GSP), designed according to the cDNA fragment isolated by differentially 
display, and adaptor primer (API or AP2). After PGR amplification, cDNA fragments 
can be cloned into AdvanTAge -Cloning vector and verified as described. Full length 
cDNA can be generated by PGR amplification using gene specific primers flanking both 
end of the putative gene after identification of the start (5’ end) and stop (3，end) codon. 
Repeat RACE reactions can be performed until reaching start and stop codons with 
GSPs designed according to the previous RACE sequence identified. 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Chemicals Company 
� A d v a n T A g e ™ PGR cloning kit Clontech Laboratories 
� H i g h pure plasmid isolation kit Boehringer Mannheim 
丁 IvI 
�Marathon cDNA amplification kit Clontech Laboratories 
�MessageClean(R) kit GenHunter Corporation 
� P C R - T R A P cloning system GenHunter Corporation 
� Q I A E X I I gel extraction kit Qiagen 
� R N A image(R) mRNA differential display system GenHunter Corporation 
�SequiTherm EXCEL™ DNA sequencing kit Epicentre Technologies 
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3.2.2 METHODS 
mRNA Differential Display 
3.2.2.1 Identification of Differentially Expressed Genes by RT-PCR 
RNA was prepared as previously described and the DNA contamination was removed 
with the MessageCleanTM Kit by the DNase I treatment. The schematic diagram was 
shown in Fig. 46. The first strand cDNAs were synthesized by reverse transcription (RT) 
with MMLV reverse transcriptase with an anchored oligo-dT primers, H-T^iG(G). 
cDNAs were amplified and radiolabeled by 40 cycles of PGR with the use of one of the 
eight arbitrary primers from set 2 of RNAimage™ Kit and a-[^^S]dATP. RT-PCR 
products from the parent and its sublines were run in parallel in 6% denaturing 
polyacrylamide gel. The gel was blotted on a piece of 3M paper and dried under 
vacuum on a gel dryer at 80°C for 2 hours. The blot was exposed to a Kodak X-ray film. 
By the signals from the X-ray film, the differentially expressed cDNA bands on the 3M 
paper were retrieved, extracted, reamplified and used it as a probe to confirm the 
differentially expressed pattern by Northern blot hybridization (Section 2.3.2.3). 
3.2.2.2 Cloning of Differentially Expressed cDNAs 
The reamplified cDNA was subcloned using pCR-TRAP vector by ligation at 16°C 
overnight. GH-competent (K12 strain) with genotype, del(lac-pro) ara thi 
((l)80dIacZdelM15) purchased from GenHunter Corporation was used for transformation 
on the next day. 10 ul of ligation mix prepared previously was added to the competent 
cells for transformation. Transformation was performed by incubation on ice for 45 min, 
then heat shock at 42°C for 2 min, and cold shock on ice for 2 min. Cells were then 
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allowed to recover by incubation for 1 hour in the presence of fresh LB medium at 3 7 � C 
before plating out on a tetracyclin containing LB agar plate. Only when PGR product 
successfully ligated in the vector, it will disrupt the repressor gene expression and turn on 
the tetracycline resistance (Tet^ )^ gene expression of the plasmid in the transformed 
bacteria. Expression of Tet^ gene allows bacteria to survive the selection of 20 i^g/ml 
tetracycline (Tet) on the agar plate. 
3.2.2.3 Screening and Sequencing of the cDNA Inserts 
After overnight incubation, 10-20 bacterial colonies on the LB plate were randomly 
picked and lysed with colony lysis buffer (0.1% Tween 20 in Tris-EDTA (TE) buffer) by 
boiling for 10 min. cDNA was collected from the supernatant of the colony lysis of the 
bacteria. The cDNA insert in the vector was checked by PGR amplification with the use 
of vector primers, Lgh (5 '-CG ACAACACCGATAATC-3') and Rgh (5'-
GACGCGAACGAAGCAAC-3'). The size of insert was analyzed by agarose gel 
electrophoresis of the PGR products and confirmed by comparing the size of the 
corresponding reamplified cDNAs. 
The corresponding Tet® colony contains an insert of interest was re-steaked to single 
colony on a new LB-Tet plate overnight at 37°C. The single Tet® colony was 
inoculated into a 5 ml LB medium. Exponentially growing bacteria were collected and 
plasmid was prepared by conventional mini-preparation. The sequence was checked by 
SequiTherm E X C E L / m DNA sequencing kit using Lgh and Rgh as primers. The 
sequence obtained was aligned with the database from Genbank using BLAST search. 
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3.2.2.4 Rapid Amplification ofcDNA Ends (RACE) 
mRNA preparation 
After getting the partial sequence of the clone of interest, the full length of the sequence 
was reamplified by the method of RACE using Marathon cDNA amplificatin kit. Poly-
A+ RNA was extracted from exponentially growing A431 cells with the use of oligo(dT)-
cellulose spun-column of QuickPrep®M/cra mRNA purification kit. Extracted mRNAs 
were quantitated by spectrophotometry, concentrated by ethanol，and made up to 0.5 
fig/ml with RNase-free water. The samples were kept at -80�C until the use for cloning 
of full length cDNA. 
3.2.2.5 Amplification Reaction 
The clone, SAPG9-25, isolated by differential display was expanded by RACE using 
Marathon cDNA and Advantage� cDNA polymerase mix. The schematic diagram is 
shown in Fig. 47. After reverse transcription, the double stranded cDNAs were ligated 
to the Marathon cDNA Adaptor. It is partially double-stranded and is phosphorylated at 
the 5'end to facilitate blunt-end ligation of the adaptor to both ends of cDNA by T4 DNA 
ligase. The adapted ligated cDNA library permitted easy amplification of the genes of 
interest simply by gene specific primer (GSP) followed with the nest gene specific primer 
(NGSP) designed according to the limited known cDNA sequence. The 5' and 3 丨 RACE 
reactions were performed with adaptor primers and gene specific primers according to the 
manufacturer's instruction. Nested gene specific primers and nested adaptor primers 
were used for the second round of amplification. The amplified PGR products were 
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analyzed on 1% agarose gel, and the DNA was transferred onto a nylon membrane for the 
subsequence Southern blot hybridization with the probe from the cDNA of SAPG9-25 to 
confirm the RACE fragment that have been amplified. 
3.2.2.6 Cloning and Sequencing of the RACE Fragments 
The amplified PGR products were subcloned into pT-Adv vector by ligation overnight at 
14°C with AdvanTAge™ PGR cloning kit. The ligated product was transformed into 
TOPIOF E.coli by incubation on ice for 30 min, heat shock at 4 2 � C for 30 sec, and cold 
shock on ice for 2 min. Cells were recovered by incubating the cells with SOC medium 
for 1 hr at 225 rpm in a rotary shaking incubator. Transformed cells were spread on 
LB/X-gal/IPTG plates containing 50 \xg/ml or either kanamycin or ampicillin in a 3 7 � C 
incubator for at least 18 hr. 
The size of the insert was checked by colony lysis, and reamplified by PGR using M13 
reverse (5 ' -GAAACAGCTATGACCATGA-3 ' ) and forward (5'-
GTTTTCCCAGTCACGAC-3') primer. The size of insert was detected by running the 
PCR product on a 1% agarose gel by electrophoresis. Minipreparation and sequencing 
were performed as discussed before. The sequence obtained was aligned with the 
database from Genbank using BLAST search. 
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3.3 RESULTS 
3.3.1 Identification of Novel cDNA by mRNA Differential Display 
cDNA band with differential expression pattern amplified by primer pair，H-T^G and the 
corresponding primer set (Table 8), was identified on the denaturing polyacrylamide gel 
(Fig. 48a). The band，disignated as SAPG9-25, was isolated and reamplified using the 
same primer set (Fig. 48b). The primer set for differential display is shown in Table 8. 
The differentially expressed pattern was verified by Northern blot analysis and the 
normalization of rRNA 18S and 28S were shown (Fig. 48c). Some other differentially 
expressed genes，namely as SAPGlO-88; SANGll-117; SANG12-265; SANG12-273; 
SANG14-291; SAPG13-444 and SANG16-467, were examined by Northern blot analysis 
(Fig. 49). 
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Table 8. Primers used in mRNA differential display 
I. One-base-anchored oligo-dT primers: 
1. H - T l l G 5'-AAGCTTTTTTTTTTTG-3‘ 
II. Arbitrary 13 mers: 
1. H-AP9 5 ‘ -AAGCTTCATTCCG-3 ‘ 
2. H-APIO 5，-AAGCTTCCACGTA-3' 
3. H-APl l 5 ‘ -AAGCTTCGGGTAA-3‘ 
4. H-AP12 5 ' -AAGCTTGAGTGCT-3 ‘ 
5. H-AP13 5 '-AAGCTTCGGCATA-3‘ 
6. H-AP14 5‘-AAGCTTGGAGCTT-3‘ 
7. H-AP15 5 ' -AAGCTTACGCAAC-3 ' 
8. H-AP16 5 '-AAGCTTTAGAGCG-3‘ 
III. Primers used in amplifying and sequencing the inserts sub-cloned in PCR-TRAP vector: 
Primer Pair (for both insert amplification and sequencing): 
1. Lgh 5 ' - C G A C A A C A C C G A T A A T C - 3 ‘ 
2. Rgh 5 ' -GACGCGAACGAAGCAAC-3 ‘ 
IV. Primers used in amplifying and sequencing the inserts sub-cloned in AdvanTAge vector: 
Primers Pairs (for both insert amplification and sequencing): 
1. Ml3 forward: 5 ' -TCGTGACTGGGAAAAC-3‘ 
2. Ml3 reverse: 5 ' -GAAACAGCTATGACCATG-3 ‘ 
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Figure 48. Examples of a gene expression profile, reamplification and colony-
PCR verification of a cDNA clone identified by mRNA differential display of 
A431 cells with the use of oligo-dT primer, H-TllG, and arbitary primer, H-
AP9. (a) The band, SAPG9-25, identified to be down-regulated in 
A431/CP500N cells, (b) This band was reamplified by PGR and the length was 
about 250bp as detected in a 1.5% agarose gel. (c) The DNA was extracted 
from the gel and used as a cDNA probe for Northern blot analysis. 
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(a) SAPG10-88 (b) SANG14-291 
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Figure 49. The differentially expressed pattern of the clones as detected by 
Northern blot analysis. 
P: A431/P cells. 
N: A431/CP500N cells. 
E: A431/CP500E cells. 
X: A431/50X30 cells. 
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After cloning, insert with the expected size was reamplified and checked by colony PGR 
using Rgh and Lgh as primers (Table 8). The PGR product after colony PGR should be 
120 bp larger than the original PGR insert before cloning due to the flanking vector 
sequence being amplified. The results of colony PGR of clone SAPG9-25 were shown 
in Figure 50a. The size is about 370 bp which is 120 bp larger than the original PGR 
product (250 bp). After the exponentially growing of the bacterial cells, the plasmid 
was obtained by minipreparation and the cDNA was reamplified by colony PGR. The 
DNA was resolved in 1.2% agarose gel by electrophoresis (Fig. 50b). The DNA on the 
gel was extracted and used as a probe for the Northern blot hybridization to confirm the 
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Figure 50. After cloning into PCR-TRAP cloning vector, 
the DNA of the bacterial colonies were extracted for PCR 
reamplification with Rgh and Lgh. (a) The size of insert 
was analyzed by agarose gel electrophoresis. (b) 
Reamplification of the SAPG9-25 cDNA. (c) The 
Northern blot hybridization. 
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After confirmation, the sequence of SAPG9-25 was read by manual cycle sequencing 
(Fig. 51a). There is 98% homology to the Homo sapiens full length insert cDNA clone 
YB26B05 (accession#: gb|AF147336.1|AF147336) after alignment to the database from 
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In order to clone the full length cDNA of gene corresponding to SAPG9-25 cDNA probe, 
rapid amplification of cDNA 5' and 3’ ends (5，and 3' RACE) was performed with the use 
of MarathonTM cDNA amplification kit and Advantage cDNA polymerase mix from 
Clontech. The schematic diagram of R A C E reaction is shown in Figure 47. After first 
and second strand cDNA synthesis, Marathon™ adaptor was ligated to both ends of the 
cDNA pool/library. 
The 5' upstream and 3' downstream unknown gene sequence can be amplified with the 
combination of GSP and adaptor primer (API) followed with the combination of nest 
gene specific primer (NGSP2) and adaptor primer (AP2). The sequences of the primers 
were shown in Table 9. The reamplified PCR product was resolved in 1% agarose gel 
(Fig. 52a). The DNA on the gel was transferred to a nylon membrane for the Southern 
blot hybridization using cDNA of SAPG9-25 as a probe (Fig. 52b). From Southern blot 
analysis, the 5' and 3' PCR fragments have about Ikb and 300bp respectively. 
The PCR product of 5，and 3，RACE fragments were cloned into pTA-vector. After 
colony PCR, the products were resolved in 1% agarose gel (Fig. 53). Several colonies 
were picked for the minipreparation and sequencing. The results of the 3，sequence 
were shown in Figure 54. However, the sequence of 5' RACE fragment cannot be 
identified, no result was obtained. 
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Table 9. Primers used for RACE 
I. Marathon cDNA Synthesis Primer and Adaptor Primers (Clontech, USA): 
1. Adaptor Primer 1 (AP1; 27-mer): 
5 ' -CCATCCTAATACGACTCACTATAGGGC-3' 
2 Nested Adaptor Primer 2 (AP2; 23-mer, sequence located downstream of AP1): 
5 '-ACTCACTATAGGGCTCGAGCGGC-3" 
11 Gene Specific Primers Designed for Full Length Cloning cDNA of SAPG9-25: 
1 5GSP1: 5'-GGGGTCAGCACTGCTCTCAACA-3' 
2 3GSP1: 5'-CCTACCCCAGCTGTCTGTTGA-3' 
3 N5GSP2: 5'-GCAGGTGGCTTTTCCTACTCGGAATG-3' 
4. N3GSP2: 5 ' -CAGTrAGGGACTGGCTGCATAGCAGAC-3' 
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Figure 52. Cloning of novel gene that is corresponding to cDNA clone SAPG9-25 as 
identified by mRNA differential display. 
(a) Reamplified PGR product of 5' and 3' RACE using 5' and 3' nested gene specific 
primers (N5GSP2 and N3GSP2) respectively with nested adaptor primer 2 (AP2). 
(b) The Southern blot hybridization of the gel from (a) using cDNA of SAPG9-25 as a 
probe. 
(a) The colony PGR of 5'RACE fragment (b) The colony PGR of 3'RACE fragment 
M M M 
I. . 
Figure 53. The colony PGR of the 5' and 3' RACE fragments where M is 
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Differential display is a powerful tool for the identification or characterization of the 
differentially expressed genes. It aims at overcoming the limitation of conventional 
gene expression analysis and cloning methodologies such as the case of subtractive 
hybridization. It is a simple and reliable method that only a small amount of initial 
materials (RNA) is required to generate the results. The identification of differentially 
expressed genes in cells would provide insights of the novel molecular mechanisms. 
The differences among the four sublines in the gene expression might provide 
information in the relationship between cisplatin resistant and EGF signalling pathway. 
In this study, a differentially expressed gene SAPG9-25 was isolated and examined, 
SAPG9-25 is down-regulated in A431/CP500N cells. Partial sequencing of this clone 
reveals that it is a novel gene. As it is down-regulated only in A431/CP500N cells, this 
clone may be cisplatin resistance related as CP500N cells are the most cisplatin resistant 
cells (Fig. 48c). The importance of SAPG9-25 in cisplatin resistance is further 
confirmed by the fact that the expression of this gene in CP500E cells is similar to the 
parent cells and so is the sensitivity of these cells to cisplatin. Furthermore, the results 
also suggest that EGF conditioned treatment may overcome the cisplatin effect thru 
down-regulation of this gene. 
Although RACE is a powerful tool to get the full length of the clone in differential 
display, the sequence of the 5'RACE fragment could not be obtained. This might be 
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due to the fact that the amplification and cloning efficiency was not high enough. 
Presence of non-specific bands was also obtained in the amplification reaction. In this 
study, only the 3'RACE fragment was cloned and sequenced. Therefore, the full-length 
SAPG9-25 could not be obtained. 
As the clone SAPG9-25 is down-regulated in CP500N cells, the over-expression of this 
gene was enhance the sensitivity of the cells to several anti-cancer drugs like cisplatin 
and doxorubicin. These anti-cancer drugs may interact with the protein or signal 
transduction pathway which is expressed by this gene. The interaction of the anti-
cancer drugs and the resultant expression of the gene product of this clone might give the 
cytotoxicity to the other sublines of A431 cells. By the induction of the gene in 
cisplatin resistance cells, the resistance phenotype might be counteracted. Further 
molecular characterization is required in order to delineate the role of SAPG9-25. 
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General Conclusion 
The cisplatin resistant cells used in this study are also cross-resistance to some of the 
anti-cancer drugs. The cross-resistance phenotype is common in most of the multi-drug 
resistant cells. The other characteristics of the cells are also reported in some other 
studies. Alteration of the growth factor signalling pathway in cells might also affect the 
drug sensitivity both in cisplatin resistant and sensitive cells. 
Cisplatin resistance in A431/CP500N cells is related to the reduction in the DNA 
fragmentation and ROS formation. The concomitant treatment of EGF and cisplatin 
would lead to the different response to anti-cancer drugs, growth factors and signal 
transduction modifiers. Cisplatin resistant cells have an over-expression of activated 
EGFR and mRNA levels. This may explain for the inhibitory effect generated by EGF 
treatment. By comparing the results of EGFR mRNA expression and the activated 
protein levels in A431/CP500N and CP500E cells, one might speculate that EGF might 
counteract the cisplatin phenotype. The activity of EGFR is deactivated upon the 
prolonged conditioning in cells. Resistance to some anti-cancer drugs in CPSOOE cells 
might be due to the over-expression of P-gp. As EGF conditioning cells were more 
resistant to 5-fluorouracil treatment, DHFR and thymindine synthase in these cells might 
be different from the cisplatin resistant cells. Although the mRNA expression of DHFR 
and thymindine synthase cannot explain the resistance to 5-fluorouracil in CPSOOE cells, 
it can explain the cytotoxicity effect on CP500N cells as those levels in CP500N cells 
were lower. 
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Results from the current studies allowed one to speculate that the application of anti-
EGFR antibody, might alter the response of cisplatin resistant cells. This might make 
the cells more sensitive to the cisplatin and some of the other anti-cancer drugs (e.g. 
doxorubicin). However, several anti-cancer drugs (e.g. 5-fluorouracil) should be 
avoided under the administration of anti-EGFR ligand. 
Differentially expressed genes can be found among the A431 sublines. A partial 
sequence of a down-regulated novel clones was performed. However，the details and 
full sequence of the clone have not yet been elucidated In order to get more 
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